US5266572A - Antipsychotic 1-cycloalkylpiperidines - Google Patents
Antipsychotic 1-cycloalkylpiperidines Download PDFInfo
- Publication number
- US5266572A US5266572A US07/900,774 US90077492A US5266572A US 5266572 A US5266572 A US 5266572A US 90077492 A US90077492 A US 90077492A US 5266572 A US5266572 A US 5266572A
- Authority
- US
- United States
- Prior art keywords
- sub
- compound
- carbon atoms
- pharmaceutically acceptable
- calcd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Definitions
- This invention relates to novel cycloalkylpiperidine compounds, pharmaceutical compositions containing them and methods of using these compounds to treat physiological or drug induced psychosis and as antidyskinetic agents.
- Ar is phenyl optionally substituted with 1 or 2 substituents selected from the group: F, Cl, Br, alkyl or alkoxy each of 1 to 4 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, CF 3 , CN, alkylthio of 1 to 4 carbon atoms, SCF 3 , OH or alkanoyloxy of 1 to 10 carbon atoms;
- R is (1-R 1 -2-pyrrolidyl)--CH 2 --CHR 2 --, (1-R 1 -2-piperidyl)-CH 2 --CHR 2 -- or 1-R 1 -3-Z-4-hexahydroazepinyl;
- R 1 is H, alkyl or alkenyl each of up to 4 carbon atoms, cyclopropylmethyl or benzyl;
- R 2 is H, alkyl of 1 to 4 carbon atoms or phenyl
- Z is alkyl of 1 to 4 carbon atoms with the proviso that Ar is p-fluorophenyl only if R is not 2-(1-methyl-2-piperidyl)-ethyl.
- the phenoxyalkylamine compounds have antidepressant activity.
- Japanese patent 48-40779 (Dainippon) describes the process for preparing compounds of the formula: ##STR1## wherein: R 1 is H, halogen, alkyl, alkoxy or trihalomethyl; and
- R 2 is alkyl, alkenyl, hydroxyalkyl, cycloalkylalkyl, dimethylaminoalkyl, aralkyl, arylalkenyl, arylalkoxy, aryloxyalkyl, 2-halophenothiazinyl(10)-propyl, 10, 11-dihydro-5H-dibenzo (b,f)azepin-5-yl-propyl or 3-halo-10,11-dihydro-5H-dibenzo (b,f)azepinyl propyl.
- R 2 is alkyl, alkenyl, benzyl, phenethyl, hydroxyethyl, cyclopropylmethyl or substituted phenylalkyl.
- antipsychotic agents have been potent dopamine receptor antagonists.
- phenothiazines such as chlorpromazine and most butyrophenones such as haloperidol are potent dopamine receptor antagonists.
- EPS extra-pyramidal side-effects
- dyskinesias including tardive dyskinesias at high doses. Many of these side effects are not reversible even after the dopamine receptor antagonist agent is discontinued.
- the present invention is related to antipsychotic agents which are selective sigma receptor antagonists rather than the traditional dopamine receptor blockers known in the art, and therefore the compounds of the present invention have low potential for the typical movement disorder side-effects associated with the dopamine antagonist antipsychotic agents while they maintain the ability to antagonize aggressive behavior and antagonize hallucinogenic-induced behavior.
- antipsychotic compounds of the present invention are cycloalkylpiperidines of the formula: ##STR3## or a pharmaceutically acceptable salt thereof, wherein: m is 0 to 3;
- n 0 to 3;
- p 0 to 3;
- X is O, S, SO, SO 2 , NR 6 , CR 7 R 8 , ##STR4## or CHOH;
- R 1 , R 3 and R 7 independently are H, alkyl of 1 to 5 carbon atoms, halogen, NR 10 OR 11 , OH, CO 2 H, carboalkoxy of 2 to 6 carbon atoms, CN, Ar 1 , alkoxy of 1 to 5 carbon atoms or alkylthio of 1 to 5 carbon atoms;
- R 2 , R 4 and R 8 independently are H, alkyl of 1 to 5 carbon atoms, carboalkoxy of 2 to 6 carbon atoms, CN, alkoxy of 1 to 5 carbon atoms or Ar 1 ;
- R 1 , R 2 , R 3 and R 4 are not alkoxy of 1 to 5 carbon atoms, alkylthio of 1 to 5 carbon atoms, NR 10 R 11 or OH when X is O, S, SO, SO 2 or NR 6 ;
- R 5 is H, alkyl, halogen, OH or alkenyl
- R 6 is H, alkyl of 1 to 5 carbon atoms or Ar 1 ;
- Ar and Ar 1 independently are naphthyl, pyridyl, pyrimidyl, indolyl, quinolinyl, isoquinolinyl, or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, SH, S(O) t alkyl of 1 to 3 carbon atoms, where t is 1, 2 or 3, dialkylamino of 2 to 6 carbon atoms, halogen, OH, alkylamino of 1 to 3 carbon atoms, CH 2 , CN, NO 2 , SO 3 H, tetrazole, CO 2 H, carboalkoxy of 2 to 6 carbon atoms, COCH 2 , SO 2 CH 2 , COR 9 , CONR 12 R 13 , SO 2 NR 12 R 13 , Ar 2 , OAr 2 or SAr 2 ;
- Ar 2 is naphthyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, alkoxy of 1 to 3 carbon atoms, halogen or alkylthio of 1 to 3 carbon atoms;
- R 9 , R 10 , R 11 , R 12 and R 13 independently are H, alkyl of 1 to 5 carbon atoms or phenyl or R 10 and R 11 taken together are an alkylene chain of 3 to 6 carbon atoms or R 12 and R 13 taken together are an alkylene chain of 3 to 6 carbon atoms; and
- a or b is a double bond or a single bond, provided that both are not double bonds.
- Preferred compounds in the present invention are those compounds of Formula (I) wherein:
- X is ##STR5## , CHOH or O;
- n 0;
- n and p are 1; and/or
- R 3 -R 5 are H;
- Ar is phenyl optionally substituted with halogen, OCH 3 , CH 2 , NO 2 or another phenyl group.
- Specifically preferred compounds of the present invention are:
- compositions comprising an effective amount of a compound of Formula (I) and a pharmaceutically acceptable carrier.
- n 0 to 3;
- p 1 to 3;
- X is O, S, NR 6 ;
- Ar and Ar 1 independently are naphthyl pyridyl, pyrimidyl, quinolinyl, isoquinolinyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, S(O) t alkyl of I to 3 carbon atoms, where t is 1, 2 or 3, dialkylamino of 2 to 6 carbon atoms, halogen, alkylamino of 1 to 3 carbon atoms, CN, NO 2 , carboalkoxy of 2 to 6 carbon atoms, COR 9 , CONR 12 R 13 , SO 2 NR 12 R 13 , Ar 2 , OAr 2 or SAr 2 ;
- Ar 2 is naphthyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, alkoxy of 1 to 3 carbon atoms, halogen or alkylthio of 1 to 3 carbon atoms;
- R 1 -R 4 and R 6 independently are H, alkyl of 1 to 5 carbon atoms or Ar 1 ;
- R 5 is H, alkyl, halogen, OH or alkenyl
- R 9 , R 12 and R 13 independently are H, alkyl of 1 to 5 carbon atoms or phenyl, or R 12 and R 13 taken together are an alkylene chain of 3 to 6 carbon atoms.
- Bases which may be used for this reaction include, but are not limited to, alkali metal hydrides, preferably sodium hydride, alkali metal carbonates, preferably potassium carbonate, alkali metal dialkylamides, preferably lithium di-isopropylamide, alkali metal bis(trialkylsilyl) amides, preferably sodium bis(trimethylsilyl)amide, alkyl alkali metal compounds (such as butyl lithium), alkali metal alkoxides (such as sodium ethoxide), alkyl alkaline earth metal halides (such as methyl magnesium bromide), trialkylamines (such as triethylamine or di-isopropylethylamine), polycyclic di-amines (such as 1,4 diazabicyclo [2.2.2]octane or 1,8-diazabicyclo-[5.4.0]undecene) or quaternary ammonium salts (such as Triton B).
- inert solvent must be compatible with the choice of base (see J. March, Advanced Organic Chemistry (New York: J. Wiley and Sons, 1985) pp. 255-446; H. O. House, Modern Synthetic Reactions (New York: W. A. Benjamin Inc., 1972, pp. 546-553)).
- Solvents include lower alkyl alcohols of 1 to 6 carbons, dialkyl ethers of 4 to 10 carbons, cyclic ethers of 4 to 10 carbons, preferably tetrahydrofuran or dioxane, dialkylformamides, preferably N,N-dimethylformamide, dialkylacetamides, preferably N,N-dimethylacetamide, cyclic amides, preferably N-methylpyrrolidinone, hydrocarbons of 5 to 10 carbons or aromatic hydrocarbons to 6 to 10 carbons.
- the leaving group Y in Formula (III) may be halide, arylsulfonyloxy, preferably p-toluenesulfonyloxy, alkylsulfonyloxy (such as methanesulfonyloxy), haloalkylsulfonyloxy, preferably trifluoromethylsulfonyloxy or acyloxy, preferably acetoxy.
- Reaction temperatures range from about -78° to 200° C., preferably about 50°-100° C.
- Compounds of Formula (IV) may be treated with reducing agents in inert solvents to afford compounds of Formula (I).
- Such reducing agents include but are not limited to, alkali metal aluminum hydrides, preferably lithium aluminum hydride, alkali metal borohydrides, preferably lithium borohydride, alkali metal trialkoxyaluminum hydrides (such as lithium tri-t-butoxyaluminum hydride), dialkylaluminum hydrides (such as di-isobutylaluminum hydride), borane, dialkylboranes (such as di-isoamyl borane), alkali metal trialkylboron hydrides (such as lithium triethylboron hydride).
- alkali metal aluminum hydrides preferably lithium aluminum hydride
- alkali metal borohydrides preferably lithium borohydride
- alkali metal trialkoxyaluminum hydrides such as lithium tri-t-butoxyaluminum hydride
- dialkylaluminum hydrides such as di-isobutylaluminum hydride
- borane dialkyl
- Inert solvents include lower alkyl alcohols of 1 to 6 carbons, ethereal solvents (such as diethyl ether or tetrahydrofuran), aromatic or non-aromatic hydrocarbons of 6 to 10 carbons.
- Reaction temperatures for the reduction range from about -78 ° to 200° C., preferably about 50° to 120° C.
- the choice of reducing agent and solvent is known to those skilled in the art as taught in the above cited March reference (pp. 1093-1110).
- Reaction temperatures range from about 50° to 80° C.
- the choices of triaryl phosphine, solvent or azodicarboxylate ester are known to those skilled in the art as described by O. Mitsunobu (Synthesis, 1 (1981]). ##STR8##
- a pyridine derivative of Formula (VII) is converted to its metallo derivative (VII*) by treatment with a metallating agent.
- metallating agents are bases, which include but are not limited to, alkali metal dialkylamides, preferably lithium di-isopropylamide, alkali metal bis(trialkylsilyl)amides, preferably lithium or sodium bis(trimethylsilyl)amides, alkali metal alkoxides, alkali metal hydrides, alkyl alkaline earth metal halides (such as methyl magnesium bromide).
- metallating agents include alkali metals, such as lithium, alkaline earth metals, such as magnesium, or alkyl lithiums, such as n-butyl lithium.
- Metallating agents include combinations of one of the above reagents and an inorganic salt such as alkaline earth metal halides or transition metal halides, preferably CuBr, ZnCl 2 or CeCl 3 .
- (VII*) may be formed in an inert solvent such as lower alkyl alcohols of 1 to 6 carbons, ethereal solvents, such as tetrahydrofuran or 1,2-dimethoxyethane, or aromatic or non-aromatic hydrocarbons of 6 to 10 carbon atoms. Temperatures for the metallation range from about -80° C. to 200° C., preferably about -78° to 70° C.
- a compound of Formula (VI) where R is alkoxyl of 1 to 6 carbons or halogen
- Reaction temperatures range from about -78° to 70° C., preferably about 0° to 70° C.
- alkylation can be conducted with or without an inert solvent.
- such solvent may be a lower alkyl alcohol of 1 to 6 carbons, an alkanenitrile, preferably acetonitrile, a halocarbon of 1 to 6 carbons, a dialkylformamide of 2 to 6 carbons, a dialkylacetamide of 3 to 7 carbons or an aromatic or non-aromatic hydrocarbon of 6 to 10 carbons.
- the intermediate (X) may be isolated upon removal of volatiles, chromatography or crystallization or (X) may be carried on to the next step in Scheme III if it is hygroscopic.
- Reducing agents include molecular hydrogen and a noble metal catalyst, preferably palladium on carbon or platinum IV oxide, alkali metal aluminum hydrides, preferably lithium aluminum hydride, alkali metal trialkoxyaluminum hydrides, dialkylaluminum hydrides, alkali metal borohydrides, preferably sodium borohydride, dialkylboron hydrides, di-imide and its precursors, alkali metal cyanoborohydrides, preferably sodium cyanoborohydride, zinc amalgam or zinc metal.
- a noble metal catalyst preferably palladium on carbon or platinum IV oxide
- alkali metal aluminum hydrides preferably lithium aluminum hydride, alkali metal trialkoxyaluminum hydrides, dialkylaluminum hydrides, alkali metal borohydrides, preferably sodium borohydride, dialkylboron hydrides, di-imide and its precursors
- alkali metal cyanoborohydrides preferably sodium cyanoborohydride, zinc amalgam or zinc metal
- Inert solvents include, but are not limited to, lower alkyl alcohols, ethereal solvent such as diethyl ether or tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbons.
- an ester of Formula (XI) (R is alkyl of 1 to 6 carbons or aralkyl of 7 to 10 carbons) is treated with an alkylating agent of Formula (IX) in the presence of a base and an inert solvent.
- the bases and inert solvents that may be used are the same as those defined for the first reaction step of Scheme I.
- the resulting ester of Formula (XII) is then converted to an aldehyde of Formula (XIII) either directly using a reducing agent or indirectly using a reducing agent then an oxidizing agent in sequence.
- the intermediate alcohol (XIV) may or may not be isolated depending on its stability using standard techniques known to those skilled in the art.
- Oxidizing agents for converting an alcohol of Formula (XIV) to an aldehyde of Formula (XIII) include transition metal oxides, such as CrO 3 or MnO 2 , pyridine-chromium complexes, such as CrO 3 .C 5 H 5 N, pyridinium dichromate or pyridinium chlorochromate, an oxalylchloride-dimethylsulfoxide-triethylamine reagent system, commonly called the Swern oxidation system (D. Swern et al., J. Organic.
- Metallating agents, and the inert solvents for such metallations include those defined for the first step of Scheme III.
- the choices of metallating agent and inert solvent are defined as for the first step of Scheme III.
- Reaction temperatures range from about -100° to 200° C., preferably about -78° to 80° C. ##STR12##
- a sulfonylating agent preferably methanesulfonyl chloride, p-toluenesulfonyl chloride or trifluoromethanesulfonic anhydride
- a base such as a trialkylamine, preferably triethylamine, an alkali metal hydride, preferably sodium hydride, an aromatic amine, preferably pyridine
- Such a sulfonylation is performed in an inert solvent such as a halocarbon of 1 to 6 carbons, preferably dichloromethane, ethereal solvents, such as diethylether or tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbons, or alkanenitriles, preferably acetonitrile.
- an inert solvent such as a halocarbon of 1 to 6 carbons, preferably dichloromethane, ethereal solvents, such as diethylether or tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbons, or alkanenitriles, preferably acetonitrile.
- a compound of Formula (XXI) (preferably where X is O 2 SCH 3 , O 2 SC 6 H 4 -CH 3 -p or O 2 SCF 3 ] is formed from such a sulfonylation and then is reacted with a nucleophilic reagent in an inert solvent to afford a compound of Formula (XXII) [Formula (I) where X is CHR 7 ].
- Such nucleophilic reagents include alkali metal alkoxides, alkali metal aluminum hydrides, dialkyl aluminum hydrides, dialkylboranes, alkyl alkaline earth halides, preferably alkyl magnesium halides, dialkyl lithium cuprates, amines of the formula HNR 10 R 11 , wherein R 10 and R 11 are as defined above, alkali metal cyanides or alkali metal alkylsulfides.
- Inert solvents include lower alkyl alcohols, alkanenitrile, preferably acetonitrile, ethereal solvents, such as diethyl ether and tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbon atoms.
- the choice of solvent is defined the same as for those in Scheme VII.
- the nucleophilic reagents include alkali metal hydrides, dialkyl aluminum hydrides, trialkyl aluminum compounds, aryl or alkyl alkaline earth halides (preferably aryl or alkyl magnesium halides), aryl or alkyl lithiums or dialkyllithium cuprates.
- an acid derivative of Formula (XXIV) [R is halogen, OH or lower alkoxy and Ar and R 3 and R 4 are as defined in Formula (I)] is reacted with an aromatic compound in the presence of a Lewis acid in an inert solvent to afford a compound of Formula (XXV).
- Lewis acids include aluminum halides, alkylsulfonic acids, preferably methanesulfonic acid, polyphosphoric acid, or acetic acid.
- Inert solvents include carbon disulfide or aromatic hydrocarbons of 6 to 10 carbons bearing electron-withdrawing substituents, such as nitrobenzene.
- a compound of Formula (XXVIII) is reacted with an aromatic compound in the presence of a Lewis acid and an inert solvent to provide a compound of Formula (XXIX).
- the choices of Lewis acid and inert solvents are defined the same as those in Scheme IX.
- Reaction temperatures range from about 0° to 150° C.
- Compounds of Formula (XXIX) may be treated with reducing agents in inert solvents to give compounds of Formula (XXX) [Formula (I) wherein m is O and X is CHOH].
- the choices of reducing agent, solvent and reaction temperature are defined the same as those for the second step of Scheme I.
- Compounds of Formula (I) may also be prepared according to Scheme XII.
- a compound of Formula (XXXIV) [wherein Z is halogen, preferably fluorine] is reacted with a compound MY [M is an alkali metal or an alkaline earth metal and Y is a nucleophile selected from the group: azide, alkoxide of 1 to 6 carbon atoms, alkylthioxide of 1 to 6 carbon atoms, cyanide, halide, NH 2 , alkylamide of 1 to 6 carbon atoms or dialkylamide of 2 to 6 carbon atoms] in an inert solvent at a reaction temperature of about 25°-200° C.
- Mass spectra (MS) or high resolution mass spectra (HRMS) were recorded on Finnegan MAT 8230 spectrometer or Hewlett Packard 5988A model spectrometer. Melting points were recorded on a Buchi Model 510 melting point apparatus and are uncorrected. Boiling points are uncorrected.
- Reagents were purchased from commercial sources and, where necessary, purified prior to use according to the general procedures outlined by D. D. Perrin and W. L. F. Armarego, Purification of Laboratory Chemicals, 3rd ed., (New York: Pergamon Press, 1988). Chromatography was performed on silica gel using the solvent systems indicated below. For mixed solvent systems, the volume ratios are given. Parts and percentages are by weight unless otherwise specified.
- the pale yellow turbid mixture was poured into a separatory funnel, washed once with a 1N hydrochloric acid solution (ice-cold, 100 mL), twice with a saturated sodium bicarbonate solution (100 mL) and once with brine (100 mL).
- reaction mixture was then stirred at reflux temperature for about 22 hours, cooled to ambient temperature, poured onto a 2N sodium hydroxide solution and mixed.
- the aqueous mixture was extracted three times with ether; the combined organic layers were washed with a 2N sodium hydroxide solution, dried over magnesium sulfate and filtered. Solvent was removed ia to give a yellow liquid.
- the compounds of Table 1 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
- the compounds of Table 2 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
- the compounds of Table 3 may be prepared according to the procedure described for Example 1C using the appropriate hydroxymethyl aromatic compound and polar solvent.
- the compounds of Table 4 may be prepared according to the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
- the compounds of Table 5 may be prepared according to the method of Example 1C using the appropriate 4-methanesulfonyloxypiperidine derivative.
- the compounds of Tables 6, 7, 8, 9 and 10 may be prepared employing the procedure described for Example 1D with the appropriate 1-(cyclopropylcarbonyl)piperidine derivative (Examples 2-220) and the appropriate reducing agent.
- the compounds of Table 11 can be prepared using the process described in Example 410, employing the appropriate acid.
- the compounds of Table 12 can be prepared using the process described in Example 410, employing the appropriate acid.
- Example 429 describes an alternate procedure to prepare the product of Example 1.
- this compound can be made as follows: Ethyl isonipecotate (48 mL, 0.31 mole), (bromomethyl)cyclopropane (85%, 50 g, 0.31 mole), and potassium carbonate (48 g, 0.35 mole) were stirred at room temperature in dry ethyl alcohol (500 mL) for 23 hours. The mixture was filtered through Celite®, rinsed with ethyl acetate and concentrated in vacuo. The resulting mixture was diluted with ethyl acetate (1 L), extracted with H 2 O (2 ⁇ 250 mL), dried (MgSO 4 ) and concentrated in vacuo. The crude product was distilled, bp 90°-115° C. at 0.8 mm Hg, to yield the product (33.8 g, 52%) as a colorless oil, which gave 1 H-NMR and MS data as listed above in Example 420 A (1).
- this compound can be made as follows: Lithium aluminum hydride (8.55 g, 0.225 mole) was added portionwise over 1 hour to az 0° C. solution of the ester from Step A above (47.6 g, 0.225 mole) in dry Et 2 O (500 mL). After 1.5 hours, the reaction was carefully quenched with H 2 O (100 mL), then filtered through Celite® and rinsed with Et 2 O. The filtrate was diluted to 1 L total volume with Et 2 O, and the phases were separated. The organic phase was extracted with brine, dried (MgSO 4 ), and concentrated in vacuo. The crude product was distilled, bp 108°-127° C. at 1.2 mm Hg, to yield the product as a colorless oil (29.3 g, 77%), which gave 1 H-NMR and MS data as listed above in Example 420 B (1).
- the compounds of Table 13 may be prepared using the procedure described for Example 429, employing the appropriate phenol.
- a solution of di-isopropylamine (4.44 g, 6.16 mL, 44 mmol) in anhydrous tetrahydrofuran (50 mL) was cooled to about 0° C. with stirring in a flame-dried flask under a nitrogen atmosphere.
- a solution of n-butyl lithium in hexane (2.5 M, 17.6 mL, 44 mmol) was added dropwise, then the reaction mixture was stirred at about 0° C. for about 15 minutes.
- a solution of 4-picoline (3.92 g, 40 mmol) in anhydrous tetrahydrofuran (50 mL) was added dropwise, then the reaction mixture was stirred at about 0° C. for about 15 minutes.
- Step 434 A(2) may be used to make an appropriate intermediate.
- the compounds of Table 14 may be prepared using, in sequence, the procedures described in Examples 434 A(1) or A(2), B and C starting with the appropriate benzoate ester.
- the compounds of Table 15 may be prepared by the procedure for Example 504 using the appropriate acid.
- the compounds in Table 16 may be prepared by the method described in Examples 1, 429 or 508 using the appropriate benzene derivative.
- the compounds in Table 17 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound.
- the compounds in Table 18 may be prepared by the methods described in Example 508 or 410, using the appropriate starting materials.
- Example 542 sodium azide (6.5 g, 100 mmol) was reacted with the product of Example 434 (1.0 g, 3.6 mmol) to afford the title compound, a solid (0.35 g): mp 140-146 (dec); MS:272; Anal.: Calcd for C 17 H 22 N 2 O.0.75H 2 O: C, 71.42, H, 8.99, N, 9.80; Found: C, 71.06, 71.03, H, 8.58, 8.54, N, 9.98, 9.99.
- hydrobromide salt Example 509, hydrobromide salt, 1.0 g
- a 1 N NaOH solution 50 mL
- the organic solution was dried over magnesium sulfate and filtered. Solvent was removed in vacuo.
- Example 429 1.0 g, 3.6 mmol
- 4-fluorophenylmagnesium bromide 1.0 M, 9 mL, 9 mmol
- tetrahydrofuran 1.0 M, 9 mL, 9 mmol
- Examples 555 through 557 were prepared according to the-methods described for Example 1A (Table 19).
- the compounds of this invention and their pharmaceutically acceptable salts possess psychotropic properties, particularly antipsychotic activity of good duration with selective sigma receptor antagonist activities while lacking the typical movement disorder side-effects of standard dopamine receptor antagonist antipsychotic agents. These compounds may also be useful as antidotes for certain psychotomimetic agents such as phencyclidine (PCP), and as antidyskinetic agents.
- PCP phencyclidine
- Brain membranes were prepared by the method of Tam (Proc. Natl. Acad. Sci. USA 80: 6703-6707, 1983). Whole brains were homogenized (20 seconds) in 10 vol (wt/vol) of ice-cold 0.34 M sucrose with a Brinkmann Polytron (setting 8). The homogenate was centrifuged at 920 ⁇ g for 10 minutes. The supernatant was centrifuged at 47,000 ⁇ g for 20 minutes. The resulting membrane pellet was resuspended in 10 vol (original wt/vol) of 50 mM Tris HCl (pH 7.4) and incubated at 37° C. for 45 minutes to degrade and dissociate bound endogenous ligands. The membranes were then centrifuged at 47,000 ⁇ g for 20 minutes and resuspended in 50 mM Tris HCl (50 mL per brain).
- Membranes were prepared from guinea pig striatum by the method described for sigma receptor binding. The membranes were then resuspended in 50 mM Tris HCl (9 mL per brain).
- IC 50 S were calculated from log-logit plots.
- haloperidol a typical antipsychotic drug
- This binding profile of haloperidol reflects the therapeutic activity as well as the motor side effects caused by antagonism of the dopamine receptors.
- the examples of this invention shown in Table I indicate potent and selective binding affinity for sigma receptors without binding to the dopamine receptors. Therefore these compounds are not expected to produce the extrapyramidal symptoms that are typical of that produced by haloperidol and other typical antipsychotics that are dopamine receptor antagonists.
- mice Male Balb/c mice (Charles River) were used. After 2 weeks of isolation in plastic cages (11.5 ⁇ 5.75 ⁇ 6 in) the mice were selected for aggression by placing a normal group-housed mouse in the cage with the isolate for a maximum of 3 minutes. Isolated mice failing to consistently attack an intruder were eliminated from the colony.
- Drug testing was carried out by treating the isolated mice with test drugs or standards. Fifteen minutes after dosing with test drugs by the oral route, one isolated mouse was removed from its home cage and placed in the home cage of another isolate. Scoring was a yes or no response for each pair. A maximum of 3 minutes was allowed for an attack and the pair was separated immediately upon an attack. Selection of home cage and intruder mice was randomized for each test. Mice were treated and tested twice a week with at least a 2 day washout period between treatments.
- haloperidol and Examples 1, 228, 409, 493 and 494 all have potent activities in inhibiting the isolation-induced aggressive behavior indicating psychotropic activities.
- mice Male Sprague-Dawley rats (CD/CR, Charles River), weighing 190-290 g, were used for surgery. In order to spare nonadrenergic neurons, rats were injected with 25 mg/kg imipramine i.p. 30 minutes before surgery. The rats were anesthetized with a 1:1.2 ratio mixture of Xylazine:Ketamine given 0.1 mL/100 g body weight i.m. A Ringers-Wydaze (100:0.01) solution was given to prevent dehydration. Dopamine was depleted in the right striatum by injecting the neurotoxin 6-hydroxydopamine (6-OHDA) into the substantia nigra of the right cerebral hemisphere.
- 6-OHDA neurotoxin 6-hydroxydopamine
- 6-OHDA Five mg was dissolved in 5 mL of a 0.04% ascorbic acid solution which had been deoxygenated with nitrogen. Five ⁇ L of the 6-OHDA solution was injected into the substantia nigra through a 26 gauge needle over a five minute period. Stereotaxic injection coordinates were -2.5 mm posterior to bregma, -2.1 mm right of the midsagittal suture, and -8.6 mm below the skull surface with the incisor bar set at +5.0 mm. Following surgery they were given 10 days to recover while housed four per cage (45.0 L ⁇ 20.0 H ⁇ 26.0 W) with ALPHA-dri bedding and ad lib access to Pro-Lab rodent chow and deionized water.
- Rotation rate and direction were determined with Coulbourn Instruments Rotometry Monitors. Clockwise and counter clockwise rotations were recorded at 30 and 60 minute intervals. The rats were examined for correct lesion location by testing for rotational activity induced by s.c. injections of 3.0 mg/kg D-amphetamine SO 4 , and 2.0 mg/kg PCP HCl, respectively. These drugs were administered in the following sequence: Amphetamine was given 30 second before testing. Seven days later, the rats were injected with PCP 30 seconds before testing. Only those rats with an ipsilateral rotation rate of 2.5 turns per minute or higher were used in subsequent tests.
- Methocel® or test drugs were administered by the oral route (p.o.) 20 minutes before testing. Phencyclidine (1.5 mg/kg) was given s.c. immediately before testing.
- both haloperidol and Example 494 have potent activity in inhibiting the potent hallucinogen PCP-induced turning behavior in rats, supporting their use for treatment of psychosis.
- haloperidol is very potent in producing catalepsy and this agrees well with the side-effect profile of haloperidol in the clinic.
- Example 494 does not produce catalepsy and suggests very low potential for extrapyramidal symptoms and tardive dyskinesia.
- Dosage forms (compositions) suitable for administration ordinarily will contain 0.5-95% by weight of the active ingredient based on the total weight of the composition.
- the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions; it can also be administered parenterally in sterile liquid dosage forms.
- Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract.
- powdered carriers such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective dis
- Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
- parenteral solutions In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
- Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
- Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
- citric acid and its salts and sodium EDTA are also used.
- parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
- Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
Description
This is a division of application Ser. No. 07/831,886, filed Feb. 6, 1992, now U.S. Pat. No. 5,243,048 which is a division of application Ser. No. 07/570,199, filed Aug. 20, 1990, now U.S. Pat. No. 5,109,002 which is a continuation-in-part of application Ser. No. 07/404,813, filed Sep. 8, 1989 now abandoned.
This invention relates to novel cycloalkylpiperidine compounds, pharmaceutical compositions containing them and methods of using these compounds to treat physiological or drug induced psychosis and as antidyskinetic agents.
U.S. Pat. No. 4,225,608 (Uhl et al.) discloses phenoxyalkylamines of the formula:
Ar--O--R
wherein:
Ar is phenyl optionally substituted with 1 or 2 substituents selected from the group: F, Cl, Br, alkyl or alkoxy each of 1 to 4 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms, CF3, CN, alkylthio of 1 to 4 carbon atoms, SCF3, OH or alkanoyloxy of 1 to 10 carbon atoms;
R is (1-R1 -2-pyrrolidyl)--CH2 --CHR2 --, (1-R1 -2-piperidyl)-CH2 --CHR2 -- or 1-R1 -3-Z-4-hexahydroazepinyl;
R1 is H, alkyl or alkenyl each of up to 4 carbon atoms, cyclopropylmethyl or benzyl;
R2 is H, alkyl of 1 to 4 carbon atoms or phenyl; and
Z is alkyl of 1 to 4 carbon atoms with the proviso that Ar is p-fluorophenyl only if R is not 2-(1-methyl-2-piperidyl)-ethyl.
The phenoxyalkylamine compounds have antidepressant activity.
Japanese patent 48-40779 (Dainippon) describes the process for preparing compounds of the formula: ##STR1## wherein: R1 is H, halogen, alkyl, alkoxy or trihalomethyl; and
R2 is alkyl, alkenyl, hydroxyalkyl, cycloalkylalkyl, dimethylaminoalkyl, aralkyl, arylalkenyl, arylalkoxy, aryloxyalkyl, 2-halophenothiazinyl(10)-propyl, 10, 11-dihydro-5H-dibenzo (b,f)azepin-5-yl-propyl or 3-halo-10,11-dihydro-5H-dibenzo (b,f)azepinyl propyl.
These compounds are described as being useful as pharmaceuticals since they exhibit psychotropic effects, however, no utility is actually documented.
Nagai et al. (Dainippon) describe psychotropic compounds of the formula: ##STR2## wherein: R1 is H, Cl or F; and
R2 is alkyl, alkenyl, benzyl, phenethyl, hydroxyethyl, cyclopropylmethyl or substituted phenylalkyl.
See: Chemical Pharmaceutical Bulletin 25(8) 1911-1922 (1979).
The 3-isomers described in Japanese Patent 48-40779 and in the Chemical Pharmaceutical Bulletin, cited above, do not show the sigma receptor selectivity demonstrated by the compounds of the present invention. It is this sigma receptor selectivity of the compounds of the present invention which makes them so advantageous over the compounds in the prior art. Traditionally, antipsychotic agents have been potent dopamine receptor antagonists. For example, phenothiazines such as chlorpromazine and most butyrophenones such as haloperidol are potent dopamine receptor antagonists. These dopamine receptor antagonists are associated with a high incidence of side effects, particularly Parkinson-like motor effects or extra-pyramidal side-effects (EPS), and dyskinesias including tardive dyskinesias at high doses. Many of these side effects are not reversible even after the dopamine receptor antagonist agent is discontinued.
The present invention is related to antipsychotic agents which are selective sigma receptor antagonists rather than the traditional dopamine receptor blockers known in the art, and therefore the compounds of the present invention have low potential for the typical movement disorder side-effects associated with the dopamine antagonist antipsychotic agents while they maintain the ability to antagonize aggressive behavior and antagonize hallucinogenic-induced behavior.
The antipsychotic compounds of the the present invention are cycloalkylpiperidines of the formula: ##STR3## or a pharmaceutically acceptable salt thereof, wherein: m is 0 to 3;
n is 0 to 3;
provided that m and n are not both O;
p is 0 to 3;
X is O, S, SO, SO2, NR6, CR7 R8, ##STR4## or CHOH; R1, R3 and R7 independently are H, alkyl of 1 to 5 carbon atoms, halogen, NR10 OR11, OH, CO2 H, carboalkoxy of 2 to 6 carbon atoms, CN, Ar1, alkoxy of 1 to 5 carbon atoms or alkylthio of 1 to 5 carbon atoms;
R2, R4 and R8 independently are H, alkyl of 1 to 5 carbon atoms, carboalkoxy of 2 to 6 carbon atoms, CN, alkoxy of 1 to 5 carbon atoms or Ar1 ;
provided that R1, R2, R3 and R4 are not alkoxy of 1 to 5 carbon atoms, alkylthio of 1 to 5 carbon atoms, NR10 R11 or OH when X is O, S, SO, SO2 or NR6 ;
R5 is H, alkyl, halogen, OH or alkenyl;
R6 is H, alkyl of 1 to 5 carbon atoms or Ar1 ;
Ar and Ar1 independently are naphthyl, pyridyl, pyrimidyl, indolyl, quinolinyl, isoquinolinyl, or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, SH, S(O)t alkyl of 1 to 3 carbon atoms, where t is 1, 2 or 3, dialkylamino of 2 to 6 carbon atoms, halogen, OH, alkylamino of 1 to 3 carbon atoms, CH2, CN, NO2, SO3 H, tetrazole, CO2 H, carboalkoxy of 2 to 6 carbon atoms, COCH2, SO2 CH2, COR9, CONR12 R13, SO2 NR12 R13, Ar2, OAr2 or SAr2 ;
Ar2 is naphthyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, alkoxy of 1 to 3 carbon atoms, halogen or alkylthio of 1 to 3 carbon atoms;
R9, R10, R11, R12 and R13 independently are H, alkyl of 1 to 5 carbon atoms or phenyl or R10 and R11 taken together are an alkylene chain of 3 to 6 carbon atoms or R12 and R13 taken together are an alkylene chain of 3 to 6 carbon atoms; and
a or b is a double bond or a single bond, provided that both are not double bonds.
Preferred compounds in the present invention are those compounds of Formula (I) wherein:
X is ##STR5## , CHOH or O; and/or
m is 0; and/or
n and p are 1; and/or
R3 -R5 are H; and/or
Ar is phenyl optionally substituted with halogen, OCH3, CH2, NO2 or another phenyl group.
Specifically preferred compounds of the present invention are:
a) 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoethyl) piperidine
b) 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoethyl) piperidine, hydrobromide salt
c) 1-(cyclopropylmethyl)-4-(2'-(4"-chlorophenyl)-2'-oxoethyl) piperidine
d) 1-(cyclopropylmethyl)-4-(2'-(4"-chlorophenyl)-2'-oxoethyl) piperidine, hydrobromide salt
e) 1-(cyclopropylmethyl)-4-(4'-fluorophenoxymethyl)piperidine
f) 1-(cyclopropylmethyl)-4-(4'-fluorophenoxymethyl)piperidine, hydrochloride salt
g) 1-(cyclopropylmethyl)-4-(4'-chlorophenoxymethyl)piperidine
h) 1-(cyclopropylmethyl)-4-(4'-chlorophenoxymethyl)piperidine, hydrochloride salt
i) 1-(cyclopropylmethyl)-4-(4'-nitrophenoxymethyl)piperidine
j) 1-(cyclopropylmethyl)-4-(2'-(4"-biphenyl)-2'-oxoethyl)piperidine
k) 1-(cyclopropylmethyl)-4-(2'-(4"-biphenyl)-2'-oxoethyl)piperidine, hydrobromide salt.
Also provided in the present invention are pharmaceutical compositions comprising an effective amount of a compound of Formula (I) and a pharmaceutically acceptable carrier.
Further provided are methods of using the compounds of Formula (I) for the treatment of physiological or drug-induced psychosis in a mammal as well as for the treatment of dyskinesias in a mammal.
Furthermore, there are provided, processes for the preparation of compounds of Formula (I).
In addition, there are provided novel intermediate compounds and methods of preparing them, useful for the preparation of some of the active compounds of this invention; said intermediate compounds having the formula: ##STR6## wherein: m is 0 to 3;
n is 0 to 3;
provided that m and n are not both O;
p is 1 to 3;
X is O, S, NR6 ;
Ar and Ar1 independently are naphthyl pyridyl, pyrimidyl, quinolinyl, isoquinolinyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, S(O)t alkyl of I to 3 carbon atoms, where t is 1, 2 or 3, dialkylamino of 2 to 6 carbon atoms, halogen, alkylamino of 1 to 3 carbon atoms, CN, NO2, carboalkoxy of 2 to 6 carbon atoms, COR9, CONR12 R13, SO2 NR12 R13, Ar2, OAr2 or SAr2 ;
Ar2 is naphthyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, alkoxy of 1 to 3 carbon atoms, halogen or alkylthio of 1 to 3 carbon atoms;
R1 -R4 and R6 independently are H, alkyl of 1 to 5 carbon atoms or Ar1 ;
R5 is H, alkyl, halogen, OH or alkenyl; and
R9, R12 and R13 independently are H, alkyl of 1 to 5 carbon atoms or phenyl, or R12 and R13 taken together are an alkylene chain of 3 to 6 carbon atoms.
Compounds of Formula (I) may be prepared according to Scheme I. In Scheme I, a compound of Formula (II) [where X is O, S, NR6 or CH2 (when m=1 and CR1 R2 =CO) or a single bond (when m=1)] is treated with a base in an inert solvent then reacted with a compound of Formula (III) to afford a compound of Formula (IV). Bases which may be used for this reaction include, but are not limited to, alkali metal hydrides, preferably sodium hydride, alkali metal carbonates, preferably potassium carbonate, alkali metal dialkylamides, preferably lithium di-isopropylamide, alkali metal bis(trialkylsilyl) amides, preferably sodium bis(trimethylsilyl)amide, alkyl alkali metal compounds (such as butyl lithium), alkali metal alkoxides (such as sodium ethoxide), alkyl alkaline earth metal halides (such as methyl magnesium bromide), trialkylamines (such as triethylamine or di-isopropylethylamine), polycyclic di-amines (such as 1,4 diazabicyclo [2.2.2]octane or 1,8-diazabicyclo-[5.4.0]undecene) or quaternary ammonium salts (such as Triton B). The choice of inert solvent must be compatible with the choice of base (see J. March, Advanced Organic Chemistry (New York: J. Wiley and Sons, 1985) pp. 255-446; H. O. House, Modern Synthetic Reactions (New York: W. A. Benjamin Inc., 1972, pp. 546-553)). Solvents include lower alkyl alcohols of 1 to 6 carbons, dialkyl ethers of 4 to 10 carbons, cyclic ethers of 4 to 10 carbons, preferably tetrahydrofuran or dioxane, dialkylformamides, preferably N,N-dimethylformamide, dialkylacetamides, preferably N,N-dimethylacetamide, cyclic amides, preferably N-methylpyrrolidinone, hydrocarbons of 5 to 10 carbons or aromatic hydrocarbons to 6 to 10 carbons. The leaving group Y in Formula (III) may be halide, arylsulfonyloxy, preferably p-toluenesulfonyloxy, alkylsulfonyloxy (such as methanesulfonyloxy), haloalkylsulfonyloxy, preferably trifluoromethylsulfonyloxy or acyloxy, preferably acetoxy. Reaction temperatures range from about -78° to 200° C., preferably about 50°-100° C. Compounds of Formula (IV) may be treated with reducing agents in inert solvents to afford compounds of Formula (I). Such reducing agents include but are not limited to, alkali metal aluminum hydrides, preferably lithium aluminum hydride, alkali metal borohydrides, preferably lithium borohydride, alkali metal trialkoxyaluminum hydrides (such as lithium tri-t-butoxyaluminum hydride), dialkylaluminum hydrides (such as di-isobutylaluminum hydride), borane, dialkylboranes (such as di-isoamyl borane), alkali metal trialkylboron hydrides (such as lithium triethylboron hydride). Inert solvents include lower alkyl alcohols of 1 to 6 carbons, ethereal solvents (such as diethyl ether or tetrahydrofuran), aromatic or non-aromatic hydrocarbons of 6 to 10 carbons. Reaction temperatures for the reduction range from about -78 ° to 200° C., preferably about 50° to 120° C. The choice of reducing agent and solvent is known to those skilled in the art as taught in the above cited March reference (pp. 1093-1110). ##STR7##
In Scheme II, a compound of Formula (II)(X=O, S, NR6) is reacted with a compound of Formula (V) in the presence of a triarylphosphine, (Ar"3P), preferably triphenylphosphine and an azodicarboxylate diester (RO2 CH═NCO2 R) wherein R is lower alkyl, and preferably diethyl azodicarboxylate in an inert solvent, preferably tetrahydrofuran or benzene. Reaction temperatures range from about 50° to 80° C. The choices of triaryl phosphine, solvent or azodicarboxylate ester are known to those skilled in the art as described by O. Mitsunobu (Synthesis, 1 (1981]). ##STR8##
In Scheme III a pyridine derivative of Formula (VII) is converted to its metallo derivative (VII*) by treatment with a metallating agent. For the case where n=1 or Y=H, such metallating agents are bases, which include but are not limited to, alkali metal dialkylamides, preferably lithium di-isopropylamide, alkali metal bis(trialkylsilyl)amides, preferably lithium or sodium bis(trimethylsilyl)amides, alkali metal alkoxides, alkali metal hydrides, alkyl alkaline earth metal halides (such as methyl magnesium bromide). For the cases where n is not equal to 1 or Y is halogen, preferably Cl or Br, metallating agents include alkali metals, such as lithium, alkaline earth metals, such as magnesium, or alkyl lithiums, such as n-butyl lithium. Metallating agents include combinations of one of the above reagents and an inorganic salt such as alkaline earth metal halides or transition metal halides, preferably CuBr, ZnCl2 or CeCl3. The metallo derivative of (VII), i.e. (VII*) may be formed in an inert solvent such as lower alkyl alcohols of 1 to 6 carbons, ethereal solvents, such as tetrahydrofuran or 1,2-dimethoxyethane, or aromatic or non-aromatic hydrocarbons of 6 to 10 carbon atoms. Temperatures for the metallation range from about -80° C. to 200° C., preferably about -78° to 70° C. Once the metallo derivative of (VII), i.e. (VII*) is formed, it is reacted in the same solvent with a compound of Formula (VI) (where R is alkoxyl of 1 to 6 carbons or halogen) to afford a compound of Formula (VIII). Reaction temperatures range from about -78° to 70° C., preferably about 0° to 70° C. A compound of Formula (VIII) is then converted to a compound of Formula (X) upon treatment with an alkylating agent of Formula (IX) (Z=halogen, alkylsulfonyloxy, or haloalkylsulfonyloxy). Such alkylation can be conducted with or without an inert solvent. When an inert solvent is used, such solvent may be a lower alkyl alcohol of 1 to 6 carbons, an alkanenitrile, preferably acetonitrile, a halocarbon of 1 to 6 carbons, a dialkylformamide of 2 to 6 carbons, a dialkylacetamide of 3 to 7 carbons or an aromatic or non-aromatic hydrocarbon of 6 to 10 carbons. The intermediate (X) may be isolated upon removal of volatiles, chromatography or crystallization or (X) may be carried on to the next step in Scheme III if it is hygroscopic. Treatment of a compound of Formula (X) with a reducing agent yields a compound of Formula (I) (where X=CHOH or C=O (depending on the reducing agent]). Reducing agents include molecular hydrogen and a noble metal catalyst, preferably palladium on carbon or platinum IV oxide, alkali metal aluminum hydrides, preferably lithium aluminum hydride, alkali metal trialkoxyaluminum hydrides, dialkylaluminum hydrides, alkali metal borohydrides, preferably sodium borohydride, dialkylboron hydrides, di-imide and its precursors, alkali metal cyanoborohydrides, preferably sodium cyanoborohydride, zinc amalgam or zinc metal. It will be apparent to those skilled in the art that some of the above reagents by themselves will only partially reduce the pyridine ring to give tetrahydropyridines among other products (See generally: the above cited March reference, pp. 1093-1110), for example structure (X'): ##STR9## In these cases, combinations of the above reagents either in tandem or sequentially must be used. Inert solvents include, but are not limited to, lower alkyl alcohols, ethereal solvent such as diethyl ether or tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbons. ##STR10##
According to Scheme IV, an ester of Formula (XI) (R is alkyl of 1 to 6 carbons or aralkyl of 7 to 10 carbons) is treated with an alkylating agent of Formula (IX) in the presence of a base and an inert solvent. The bases and inert solvents that may be used are the same as those defined for the first reaction step of Scheme I. The resulting ester of Formula (XII) is then converted to an aldehyde of Formula (XIII) either directly using a reducing agent or indirectly using a reducing agent then an oxidizing agent in sequence. In the latter course, the intermediate alcohol (XIV) may or may not be isolated depending on its stability using standard techniques known to those skilled in the art. Reducing agents and the inert solvents for the reduction include those defined in Schemes I and III. Oxidizing agents for converting an alcohol of Formula (XIV) to an aldehyde of Formula (XIII) include transition metal oxides, such as CrO3 or MnO2, pyridine-chromium complexes, such as CrO3.C5 H5 N, pyridinium dichromate or pyridinium chlorochromate, an oxalylchloride-dimethylsulfoxide-triethylamine reagent system, commonly called the Swern oxidation system (D. Swern et al., J. Organic. Chem., 43, 2480-2482 (1978)) or a dimethyl sulfoxide-dicyclohexylcarbodiimide system (See: H. O. House, Modern Synthetic Reactions (New York: W. A. Benjamin Inc., 1972) pp. 416-421). Such oxidations, when necessary, employ an inert solvent such as those employed for the reduction or halocarbons of 1 to 6 carbons, preferably dichloromethane or 1,2-dichloroethane. A compound of Formula (XIII) is then converted to a compound of Formula (XVI) [Formula (I) where X=CHOH] by reaction with a metallo derivative of a compound of Formula (XV). Such a metallo derivative is prepared by treatment with a base (X=H) or other metallating agents (X=halogen). Metallating agents, and the inert solvents for such metallations, include those defined for the first step of Scheme III. A compound of Formula (XVI) [Formula (I) where X=CHOH] is oxidized to a compound of Formula (XVII) (Formula (I) where X=CO] using an oxidizing agent and inert solvent, both of which are defined the same as for the second step of Scheme IV. ##STR11##
Alternatively, some of the compounds of this invention may be prepared using the procedures shown in Scheme V. A compound of Formula (XVIII) is converted to its metallo derivative with either a base (if Y=H, halogen) or other metallating agents (if Y=halogen) in an inert solvent. The choices of metallating agent and inert solvent are defined as for the first step of Scheme III. Such a metallo derivative is reacted with an aldehyde of Formula (XIX) in the same inert solvent to afford a compound of Formula (XVI) (Formula (I) where X=CHOH]. Reaction temperatures range from about -100° to 200° C., preferably about -78° to 80° C. ##STR12##
Some of the compounds of this invention may be prepared according to Scheme VI. A compound of Formula (XVII) [Formula (I) where X=CO] is reacted with an amine of Formula HNR10 R11 in the presence of a reducing agent in an inert solvent to give a compound of Formula (XX) [Formula (I) where X=CHNR10 R11 ]. The choices of reducing agent and inert solvent are defined the same as for these in the last step of Scheme III. R10 and R11 independently may be H or alkyl of 1 to 6 carbons or taken together are an alkylene chain of 2 to 6 carbons. When R10 and R11 are both H, an ammonium salt is used (preferably ammonium acetate) according to the prior art (see pp. 45-100 of House, Modern Synthetic Reaction, cited supra). ##STR13##
According to Scheme VII, a compound of Formula (XVI) [Formula I where X=CHOH] is treated with a sulfonylating agent, preferably methanesulfonyl chloride, p-toluenesulfonyl chloride or trifluoromethanesulfonic anhydride, in the presence of a base, such as a trialkylamine, preferably triethylamine, an alkali metal hydride, preferably sodium hydride, an aromatic amine, preferably pyridine, or an alkali metal carbonate or alkoxide. Such a sulfonylation is performed in an inert solvent such as a halocarbon of 1 to 6 carbons, preferably dichloromethane, ethereal solvents, such as diethylether or tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbons, or alkanenitriles, preferably acetonitrile. A compound of Formula (XXI) (preferably where X is O2 SCH3, O2 SC6 H4 -CH3 -p or O2 SCF3 ] is formed from such a sulfonylation and then is reacted with a nucleophilic reagent in an inert solvent to afford a compound of Formula (XXII) [Formula (I) where X is CHR7 ]. Such nucleophilic reagents include alkali metal alkoxides, alkali metal aluminum hydrides, dialkyl aluminum hydrides, dialkylboranes, alkyl alkaline earth halides, preferably alkyl magnesium halides, dialkyl lithium cuprates, amines of the formula HNR10 R11, wherein R10 and R11 are as defined above, alkali metal cyanides or alkali metal alkylsulfides. Inert solvents include lower alkyl alcohols, alkanenitrile, preferably acetonitrile, ethereal solvents, such as diethyl ether and tetrahydrofuran, aromatic or non-aromatic hydrocarbons of 6 to 10 carbon atoms.
According to Scheme VIII, a compound of Formula (XVII) (Formula (I) where X=CO] is reacted with a nucleophilic reagent in an inert solvent to give a compound of Formula (XXIII) [Formula (I) where X=CR6 R7 where R6 and R7 are as defined in Formula (I)]. The choice of solvent is defined the same as for those in Scheme VII. The nucleophilic reagents include alkali metal hydrides, dialkyl aluminum hydrides, trialkyl aluminum compounds, aryl or alkyl alkaline earth halides (preferably aryl or alkyl magnesium halides), aryl or alkyl lithiums or dialkyllithium cuprates. ##STR14##
According to Scheme IX an acid derivative of Formula (XXIV) [R is halogen, OH or lower alkoxy and Ar and R3 and R4 are as defined in Formula (I)] is reacted with an aromatic compound in the presence of a Lewis acid in an inert solvent to afford a compound of Formula (XXV). Lewis acids include aluminum halides, alkylsulfonic acids, preferably methanesulfonic acid, polyphosphoric acid, or acetic acid. Inert solvents include carbon disulfide or aromatic hydrocarbons of 6 to 10 carbons bearing electron-withdrawing substituents, such as nitrobenzene. Compounds of Formula (XXV) are then converted to pyridinium salts (XXVI) with alkylating agents (IX). These compounds of Formula (XXVI) are then treated with reducing agents in an inert solvent to afford compounds of Formula (XXVII) (Formula (I), wherein m is O and X is CO]. The choices of alkylating agent (IX), reducing agent, inert solvents and reaction temperatures are the same as those defined in Scheme III. ##STR15##
Alternatively, according to Scheme X, a compound of Formula (XXVIII) is reacted with an aromatic compound in the presence of a Lewis acid and an inert solvent to provide a compound of Formula (XXIX). The choices of Lewis acid and inert solvents are defined the same as those in Scheme IX. Reaction temperatures range from about 0° to 150° C. Compounds of Formula (XXIX) may be treated with reducing agents in inert solvents to give compounds of Formula (XXX) [Formula (I) wherein m is O and X is CHOH]. The choices of reducing agent, solvent and reaction temperature are defined the same as those for the second step of Scheme I. Compounds of Formula (XXX) may be oxidized to compounds of Formula (XXXI) (Formula (I) wherein m is O and X=CO]. The choices of oxidizing agents, solvents and reaction temperatures are defined the same as those for the oxidation of compounds of Formula (XIV) to compounds of Formula (XIII) in Scheme (IV). ##STR16##
Compounds of Formula (I) may also be made according to Scheme XI. A compound of formula ArZ is reacted with a compound of Formula (XXXII) (X is O, S or NR6) in the presence of a base and an inert solvent to yield a compound of Formula (XXXIII) (Formula (I) wherein m is O]. Ar is preferably a phenyl ring substituted with an electron withdrawing group or a heteroaryl ring. Z is halogen, preferably fluorine or chlorine. The choices for base and solvent are as defined in the first step of Scheme I. ##STR17##
Compounds of Formula (I) may also be prepared according to Scheme XII. A compound of Formula (XXXIV) [wherein Z is halogen, preferably fluorine] is reacted with a compound MY [M is an alkali metal or an alkaline earth metal and Y is a nucleophile selected from the group: azide, alkoxide of 1 to 6 carbon atoms, alkylthioxide of 1 to 6 carbon atoms, cyanide, halide, NH2, alkylamide of 1 to 6 carbon atoms or dialkylamide of 2 to 6 carbon atoms] in an inert solvent at a reaction temperature of about 25°-200° C. and preferably 100°-150° C., to yield a compound of Formula XXXV (Formula I, wherein m is 0 and X is C═O]. The inert solvent may be the same as those defined in the first step of Scheme I. Compounds of formula MY may be generated in situ from a compound of formula HY and a base chosen from the bases defined for the first step of Scheme I. ##STR18##
Analytical data were recorded for the compounds described below using the following general procedures. Infrared spectra were recorded on a Perkin-Elmer Model 1600 FT-IR spectrometer; absorbances are recorded in cm-1 and intensities are denoted s (strong), m (moderate) and w (weak). Proton NMR spectra were recorded on a IBM-Bruker FT-NMR spectrometer (200 MHz or 300 MHz); chemical shifts were recorded in ppm (δ) from an internal tetramethylsilane standard in deuterochloroform or deuterodimethylsulfoxide and coupling constants (J) are reported in Hz. Mass spectra (MS) or high resolution mass spectra (HRMS) were recorded on Finnegan MAT 8230 spectrometer or Hewlett Packard 5988A model spectrometer. Melting points were recorded on a Buchi Model 510 melting point apparatus and are uncorrected. Boiling points are uncorrected.
Reagents were purchased from commercial sources and, where necessary, purified prior to use according to the general procedures outlined by D. D. Perrin and W. L. F. Armarego, Purification of Laboratory Chemicals, 3rd ed., (New York: Pergamon Press, 1988). Chromatography was performed on silica gel using the solvent systems indicated below. For mixed solvent systems, the volume ratios are given. Parts and percentages are by weight unless otherwise specified.
Intermediate compounds of Formula (IV) (where X=O) are exemplified in the following Tables 1-5, these intermediate compounds are then further reduced by various processes to yield some of the active antipsychotic compounds of Formula (I) (Tables 6-10). Compounds of Formula (I) are further exemplified in Tables 11-17.
A solution of 1-(cyclopropylcarbonyl)-4-carboethoxy piperidine (35 g, 156 mmol) in anhydrous tetrahydrofuran (350 mi) was stirred at ambient temperature under a nitrogen atmosphere. A solution of lithium borohydride in tetrahydrofuran (2M, 78 mL, 156 mmol) was added dropwise. Trimethyl borate (1.77 mL, 15.7 mmol) was added, then the reduction mixture was stirred for about 48 hours. Water was added dropwise with vigorous stirring until the vigorous gas evolution ceased. The mixture was diluted twofold with water and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo. Vacuum distillation (bp 165° C., 0.5 mm Hg) gave a clear, colorless liquid (18.2 g): IR (neat): 3410 (br s), 3094 (w), 3008 (s), 2918 (s), 2858 (s), 1738 (m), 1613 (s), 1448 (s), 1375 (s), 1316 (s); 1 H-NMR: 4.7-4.5 (m, 1H), 4.4-4.1 (m, 1H), 3.6-3.4 (m, 2H), 3.2-2.5 (m, 3H), 2.0-1.7 (m, 4H), 1.4-1.1 (m, 1H), 1.0-0.8 (m, 2H), 0.8-0.65 (m, 2H); HRMS: Calcd for C10 H17 NO2 : 183.1259; Found: 183.1250; Anal.: Calcd for C10 H17 NO2 : C, 65.54, H, 9.35, N, 7.64; Found: C, 65.83, H, 9.43, N, 7.50.
A solution of 1-(cyclopropylcarbonyl)-4-hydroxymethyl-piperidine from Step A (6.0 g, 33 mmol) and triethylamine (11.9 g, 16.4 mL, 118 mmol) in dichloromethane (150 mL) was stirred at about 0° C. under a nitrogen atmosphere. A solution of methanesulfonyl chloride (4.5 g, 3.0 mL, 39 mmol) in dichloromethane (20 mL) was added dropwise. The reaction mixture was then stirred at about 0°-5° C. for 35 minutes. The pale yellow turbid mixture was poured into a separatory funnel, washed once with a 1N hydrochloric acid solution (ice-cold, 100 mL), twice with a saturated sodium bicarbonate solution (100 mL) and once with brine (100 mL). The organic solution was dried over magnesium sulfate, filtered and concentrated in vacuo to give a pale yellow oil (8.5 g): 1 H-NMR: 4.8-4.5 (m, 1H), 4.4-4.2 (m, 1H), 4.2-3.95 (m, 2H), 3.2-2.8 (m, 4H), 2.7-2.5 (m, 1H), 2.2-1.6 (m, 4H), 1.5-1.1 (m, 2H), 1.05-0.9 (m, 2H), 0.85-0.7 (m, 2H); MS: 261.
Sodium hydride (50% in oil, 1.0 g, 20 mmol) was washed with hexanes twice, then suspended in anhydrous tetrahydrofuran (20 mL) with stirring under a nitrogen atmosphere. A solution of 4-fluorophenol (2.13 g, 19 mmol) in tetrahydrofuran (10 mL) was added dropwise with vigorous gas evolution. The reaction mixture was stirred at room temperature for 15 minutes, then a solution of 1-cyclopropylcarbonyl-4-methanesulfonyloxypiperidine (983 mg, 3.77 mmol) from Step B, in tetrahydrofuran (10 mL) was added dropwise. The reaction mixture was then stirred at reflux temperature for about 22 hours, cooled to ambient temperature, poured onto a 2N sodium hydroxide solution and mixed. The aqueous mixture was extracted three times with ether; the combined organic layers were washed with a 2N sodium hydroxide solution, dried over magnesium sulfate and filtered. Solvent was removed ia to give a yellow liquid.
Column chromatography (ethyl acetate) gave, after removal of solvent in vacuo, the product, a clear, colorless liquid (617 mg): 1 H-NMR: 7.05-6.73 (m, 4H), 4.8-4.55 (br M, 1H), 4.45-4.2 (m, 1H), 3.9-3.6 (br s, 2H), 3.25-3.0 (br t, 1H, J=6), 2.8-2.5 (br t, 1H, J=6), 2.2-1.7 (m, 4H), 1.5-1.2 (m, 2H), 1.05-0.9 (m, 2H), 0.8-0.7 (m, 2H); HRMS: Calcd for C16 H20 FNO2 : 277.1478; Found: 277.1466; Anal.: Calcd for C16 H20 FNO2 : C, 69.29, H, 7.27, N, 5.05, F, 6.85; Found: C, 69.14, H, 7.41, N, 5.04, F, 7.04.
A solution of 1-(cyclopropylcarbonyl)-4-(41 -fluorophenoxymethyl)piperidine (316 mg, 1.14 mmol) in anhydrous tetrahydrofuran (5 mL) was stirred at ambient temperature under a nitrogen atmosphere. A solution of lithium aluminum hydride in tetrahydrofuran (1M, 10 mL, 10 mmol) was added dropwise via syringe. The reaction mixture was then stirred at reflux temperature for 24 hours, then it was cooled to room temperature. Ethyl acetate (10 mL) was added dropwise, then water (0.5 mL), a 2N sodium hydroxide solution (0.5 mL), water (1.5 mL) were added sequentially. The resulting suspension was filtered through Celite® the inorganic salts were washed with copious amounts of ethyl acetate. The filtrate was dried over magnesium sulfate and filtered. Solvent was removed in vacuo to give the product, a pale yellow white solid (266 mg, 89% yield): 1 H-NMR:7.0-6.7 (m, 4H), 3.7 (d, 3H, J=7), 3.05 (br d, 2H, J=10), 2.2 (d, 2H, J=7), 2.0-1.6 (m, 4H), 1.5-1.25 (m, 2H), 0.95-0.75 (m, 1H), 0.65-0.5 (m, 2H), 0.1-0.0 (m, 2H); MS: 263; Anal.: Calcd. for C16 H22 FNO.0.5H2 O: C, 70.50, H, 8.23, N, 5.52; Found: C, 70.49, H, 8.44, N, 5.14.
The compounds of Table 1 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
TABLE 1
______________________________________
##STR19## (II)
Ex. R mp (°C.)
______________________________________
1C 4-F (a)
2 4-Cl 82-83(b)
3 4-CH.sub.3 O 54-56(c)
4 H
5 4-Br
6 4-I
7 4-NO.sub.2
8 4-(CH.sub.3).sub.2 N
9 4-NHCOCH.sub.3
10 4-CH.sub.3
11 4-t-C.sub.4 H.sub.9
105-109(d)
12 4-C.sub.2 H.sub.5 O
13 4-NHCHO
14 4-CO.sub.2 CH.sub.3
111-112(e)
15 4-COCH.sub.3 98-101(f)
16 4-SCH.sub.3 107-109(g)
17 4-SO.sub.2 N(CH.sub.3).sub.2
18 4-CF.sub.3
19 4-CCl.sub.3
20 4-CH.sub.2 CF.sub.3
21 4-COCF.sub.3
22 4-CH.sub.2 CH.sub.2 F
23 4-SCOCH.sub.3
24 4-CN
25 4-CON(CH.sub.3).sub.2
26 4-N.sub.3
27 4-CHCH.sub.2
28 4-C.sub.6 H.sub.5
(h)
29 3-Cl
30 3-Br
31 3-I
32 3-F
33 3-CH.sub.3 O
34 3-C.sub.2 H.sub.5 O
35 3-CH.sub.3
36 3-C.sub.2 H.sub.5
37 3-CO.sub.2 CH.sub.3
38 3-COCH.sub.3
39 3-CF.sub.3
40 3-CCl.sub.3
41 3-CH.sub.2 CF.sub.3
42 3-COCF.sub.3
43 3-CH.sub.2 CH.sub.2 F
44 3-CN
45 3-CON(CH.sub.3).sub.2
46 3-CHO
47 3-N.sub.3
48 3-NHCHO
49 3-NHCOCH.sub.3
50 3-NO.sub.2
51 3-(CH.sub.3).sub.2 N
(i)
52 3-SCH.sub.3
53 3-SO.sub.2 N(CH.sub.3).sub.2
54 3-SCOCH.sub.3
55 2-F
56 2-Br
57 2-Cl
58 2-I
59 2-CH.sub.3 O
60 2-CH.sub.3
61 2-CO.sub.2 CH.sub.3
62 2-COCH.sub.3
63 2-CF.sub.3
64 2-CCl.sub.3
65 2-CH.sub.2 CF.sub.3
66 2-COCF.sub.3
67 2-CH.sub.2 CH.sub.2 F
68 2-CN
69 2-CON(CH.sub.3).sub.2
70 2-CHO
71 2-N.sub.3
72 2-NHCHO
73 2-NHCOCH.sub.3
74 2-NO.sub.2
75 2-SCH.sub.3
76 3,4-F.sub.2 (j)
77 3,4-Cl.sub.2 (k)
78 3,4-(CH.sub.3 O).sub.2
79 2,6-Br.sub.2 -4-CH.sub.3
80 2,6-Br.sub.2 -4-NO.sub.2
81 2,4-Cl.sub.2 -6-NO.sub.2
82 2,4-Cl.sub.2
83 3,5-Cl.sub.2
84 3-(CH.sub.2 H.sub.5).sub.2 N
85 2,4-F.sub.2
86 2,3-F.sub.3
87 2,3-(CH.sub.3 O).sub.2
88 3,4-(CH.sub.3).sub.2
89 2,4-(CH.sub.3).sub.2
90 2,4-(NO.sub.2).sub.2
91 3-(OC.sub.2 H.sub.5)4-OCH.sub.3
92 4-(OCH.sub.3)-3(OC.sub.2 H.sub.5)
93 5-F-2-NO.sub.2
94 2-(CH.sub.3 O)-4-(NO.sub.2)
95 3-(CH.sub.3 O)-4-(NO.sub.2)
96 3,4-OCH.sub.2 O
97 3-CH.sub.3 -4-NO.sub.2
98 4-CH.sub.3 -3-NO.sub.2
99 2-CH.sub.3 -3-NO.sub.2
100 2-NO.sub.2 -3-CH.sub.3
101 F.sub.5 (l)
102 Br.sub.5
103 Cl.sub.5
104 2,3,5,6-F.sub.4
105 2,3,5,6-Cl.sub.4
106 2,3,5,6-Br.sub.4
107 2,4,5-F.sub.3
108 2,4,5-Cl.sub.3
109 2,4,5-Br.sub.3
110 3,4,5-(CH.sub.3 O).sub.3
108-110(m)
111 4-C.sub.6 H.sub.5 O
109-110(n)
112 4-F-C.sub.6 H.sub.4
133-135(o)
113 4-CH.sub.3 OC.sub.6 H.sub.4
143-145(p)
______________________________________
Footnotes for Table 1
(a) Anal.: Calcd for C.sub.16 H.sub.20 FNO.sub.2 : C, 69.29, H, 7.27, N,
5.05,
F, 6.85; Found: C, 69.14, H, 7.41, N, 5.04, F, 7.04.
(b) Anal.: Calcd for C.sub.16 H.sub.20 ClNO.sub.2 : C, 65.41, H, 6.86,
N, 4.77,
Cl, 12.07; Found: C, 65.18, H, 6.77, N, 4.67, Cl, 12.14.
(c) Anal.: Calcd for C.sub.17 H.sub.23 NO.sub.3 : C, 70.56, H, 8.01, N,
4.84;
Found: C, 70.59, H, 8.02, N, 4.94.
(d) .sup.1 H-NMR (CDCl.sub.3): 7.4-7.2(m, 2H), 6.9-6.7(m, 2H),
4.8-4.6(m, 1H), 3.9-3.7(m, 2H), 3.2-3.0(m, 1H), 2.7-2.5(m,
1H), 2.1-1.7(m, 3H), 1.5-1.3(m, 7H), 1.3(s, 9H); MS: 315.
(e) Anal.: Calcd for C.sub.18 H.sub.23 NO.sub.4 : C, 68.12, H, 7.30, N,
4.41;
Found: C, 68.20, H, 7.48, N, 4.63.
(f) .sup.1 H-NMR (CDCl.sub.3): 8.0(d, 2H, J=8), 6.9(d, 2H, J=8),
4.7(m, 1H), 4.4(m, 1H), 3.9(m, 2H), 3.2(m, 1H), 2.7(m, 1H),
2.6(s, 3H), 2.2-1.7(m, 4H), 1.4(m, 2H); MS: 301.
(g) Anal.: Calcd for C.sub.17 H.sub.23 NO.sub.2 S: C, 66.85, H, 7.59, N,
4.58,
S, 10.67; Found: C, 66.92, H, 7.74, N, 4.46, S, 10.23
(h) .sup.1 H-NMR (CDCl.sub.3): 7.6-7.2(m, 7H), 7.0(d, 2H, J=7),
4.8-4.6(m, 1H), 4.4-4.2(m, 1H), 3.9(br s, 2H), 3.3-3.1(m,
2H), 2.8-2.6(m, 2H), 2.2-1.7(m, 3H), 1.4-1.2(m, 1H),
1.1-0.9(m, 2H), 0.9-0.7(m, 2H).
(i) .sup.1 H-NMR (CDCl.sub.3): 7.15(t, 1H, J=8), 6.15(d, 1H, J=9),
6.1-6.0(m, 2H), 4.7-4.55(m, 1H), 4.35-4.2(m, 1H), 3.9-3.7(m,
2H), 3.2-3.0(m, 1H), 2.9(s, 6H), 2.8-2.5(m, 1H), 2.2-1.7(m,
4H), 1.5-1.2(m, 2H), 1.05-0.9(m, 2H), 0.8-0.65(m, 2H);
HRMS: Calcd for C.sub.18 H.sub.26 N.sub.2 O.sub.2 : 302.1994; Found:
302.1994.
(j) .sup.1 H-NMR (CDCl.sub.3, 300 MHz): 7.05(q, 1H, J=8),
6.75-6.65(m, 1H), 6.65-6.5(m, 1H), 4.75-4.6(m, 1H),
4.4-4.2(m, 1H), 3.85-3.7(m, 2H), 3.15(br t, 1H, J=7),
2.65(br t, 1H, J=7), 2.15-1.7(m, 4H), 1.5-1.2(m, 2H),
1.1-0.9(m, 2H), 0.9-0.75(m, 2H); HRMS: Calcd for
C.sub.16 H.sub.19 F.sub. 2 NO.sub.2 : 295.1384; Found: 295.1385
(k) .sup.1 H-NMR (CDCl.sub.3): 7.4-7.2(m, 1H), 7.05-6.95(m, 1H),
6.8-6.65(m, 1H), 4.8-4.55(m, 1H), 4.4-4.2(m, 1H), 3.9-3.7(m,
2H), 3.3-3.0(m, 1H), 2.8-2.5(m, 1H), 2.2-1.7(m, 4H),
1.5-1.2(m, 2H), 1.06-0.9(m, 2H), 0.85-0.7(m, 2H); HRMS:
Calcd for C.sub.16 H.sub.19 Cl.sub.2 NO.sub.2 : 327.0793; Found:
327.0788.
(l) .sup.1 H-NMR (CDCl.sub.3): 4.75-4.55(m, 1H), 4.4-4.2(m, 1H),
4.1-3.9(m, 2H), 3.25-3.05(m, 1H), 2.75-2.5(m, 1H),
2.2-1.7(m, 3H), 1.5-1.2(m, 2H), 1.05-0.9(m, 2H), 0.85-0.6(m,
2H); Calcd for C.sub.16 H.sub.16 F.sub.5 NO.sub.2 : 329.1101; Found:
349.1100.
(m) Anal.: Calcd for C.sub.19 H.sub.27 NO.sub.5 : C, 65.31, H, 7.79, N,
4.01;
Found: C, 65.41, H, 7.76, N, 4.26.
(n) Anal.: Calcd for C.sub.22 H.sub.25 NO.sub.2 : C, 75.19, H, 7.17, N,
3.99;
Found: C, 75.15, H, 7.12, N, 3.91.
(o) .sup.1 H-NMR (DMSO, 300 MHz): 7.65(dd, 2H, J=8, 6), 7.55(d,
2H, J=8), 7.3(t, 2H, J=8), 7.05(d, 2H, J=8), 4.5-4.3(m,
2H), 3.9(d, 2H, J=7), 3.2-3.0(m, 1H), 2.7-2.55(m, 1H),
2.1-1.7(m, 4H), 1.4-1.05(m, 2H), 0.85-0.6(m, 4H); MS: 354.
(p) .sup.1 H-NMR (DMSO, 300 MHz): 7.55(2×d, 4H, J=8), 7.0(d,
4H, J=8), 4.5-4.3(m, 2H), 3.9(d, 2H, J=7), 3.8(s, 3H),
3.2-3.1(m, 1H), 2.7-2.6(m, 1H), 2.1-1.75(m, 4H), 1.35-1.1(m,
2H), 0.8-0.6(m, 4H); HRMS: Calcd for C.sub.23 H.sub.27 NO.sub.3 :
365.1991; Found: 365.2001.
The compounds of Table 2 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
TABLE 2
______________________________________
##STR20## (II)
Ex. Ar mp (°C.)
______________________________________
114 2-naphthyl 150-152(a)
115 1-naphthyl
116 2,4-dichloro-1-naphthyl
117 4-indolyl
118 5-indolyl
119 5-isoquinolinyl
120 4-pyridyl (b)
121 3-pyridyl
122 2-methyl-4-quinolinyl
123 3-nitro-2-pyridyl
124 4-quinolinyl (c)
125 5-quinolinyl
126 5-pyrimidyl
______________________________________
Footnotes for Table 2
(a) Anal.: Calcd for C.sub.20 H.sub.23 NO.sub.2.0.2H.sub.2 O: C, 76.75,
H, 7.53, N,
4.47; Found: C, 76.91, 76.89, H, 7.60, 7.53, N, 4.56, 4.32.
(b) .sup.1 H-NMR (CDCl.sub.3): 8.45(d, 2H, J=6), 6.8(d, 2H, J=6),
4.7(br d, 1H, J=10), 4.3(br d, 1H, J=10), 3.95-3.8(m, 2H),
3.15(br t, 1H, J=10), 2.65(br t, 1H, J=10), 2.2-1.75(m, 4H),
1.5-1.25(m, 2H), 1.05-0.95(m, 2H), 0.8-0.65(m, 2H); HRMS:
Calcd for C.sub.15 H.sub.20 N.sub.2 O.sub.2 : 260.1525; Found:
260.1537.
(c) .sup.1 H-NMR(CDCl.sub.3): 8.7(d, 1H, J=6), 8.2(d, 1H, J=8), 8.05(d,
1H, J=8), 7.7(td, 1H, J= 6, 1), 7.5(t, 1H, J=6), 6.7(d, 1H,
J=6), 4.75(br d, 1H, J=10), 4.35(br d, 1H, J=10),
4.15-4.0(m, 2H), 3.2(br t, 1H, J=10, 2.7(br t, 1H, J=10);
HRMS: Calcd for C.sub.19 H.sub.22 N.sub.2 O.sub.2 : 310.1681; Found:
310.1690.
The compounds of Table 3 may be prepared according to the procedure described for Example 1C using the appropriate hydroxymethyl aromatic compound and polar solvent.
TABLE 3 ______________________________________ ##STR21## (II) Ex. R mp (°C.) ______________________________________ 127 4-F 128 4-Cl 129 4-Br 130 4-I 131 H 132 4-CH.sub.3 O 133 4-C.sub.2 H.sub.5 O 134 4-TBDMSO (a) 135 4-NO.sub.2 136 4-(CH.sub.3).sub.2 N 137 4-NHCOCH.sub.3 138 4-N.sub.3 139 4-CH.sub.3 140 4-C.sub.2 H.sub.5 141 4-CO.sub.2 CH.sub.3 142 4-COCH.sub.3 143 4-CF.sub.3 144 4-CHO 145 4-CN 146 4-CON(CH.sub.3).sub.2 147 4-SCH.sub.3 148 3-F 149 3-Cl 150 3-Br 151 3-I 152 3-CH.sub.3 O 153 3-C.sub.2 H.sub.5 O 154 3-CH.sub.3 155 3-C.sub.2 H.sub.5 156 3-CO.sub.2 CH.sub.3 157 3-COCH.sub.3 158 3-CF.sub.3 159 3-CN 160 3-CON(CH.sub.3).sub.2 161 3-CHO 162 3-N.sub.3 163 3-NO.sub.2 164 3-NHCOCH.sub.3 165 3-NHCHO 166 3-(CH.sub.3).sub.2 N 167 3-SCH.sub.3 168 3-SO.sub.2 N(CH.sub.3).sub.2 169 2-F 170 2-Cl 171 2-Br 172 2-I 173 2-CH.sub.3 O 174 2-CH.sub.3 175 2-CO.sub.2 CH.sub.3 176 2-COCH.sub.3 177 2-CF.sub.3 178 2-CN 179 2-N.sub.3 180 2-NHCHO 181 2-NHCOCH.sub.3 182 2-NO.sub.2 183 2-SCH.sub.3 184 3,4-F.sub.2 185 3,4-Cl.sub.2 186 3,4-(CH.sub.3 O).sub.2 187 2,4-Cl.sub.2 188 2,4-F.sub.2 189 2,4-(CH.sub.3 O).sub.2 190 3,4-F.sub.2 191 3,5-Cl.sub.2 192 3,4-(CH.sub.3).sub.2 193 2,4-(NO.sub.2).sub.2 194 3,4-(NO.sub.2).sub.2 195 3-CH.sub.3 O-4-NO.sub.2 196 4-CH.sub.3 O-3-NO.sub.2 197 3,4-OCH.sub.2 O 198 F.sub.5 199 Cl.sub.5 200 3,4,5-(CH.sub.3 O).sub.3 ______________________________________ Footnote for Table 3 (a) TBDMS = tbutyldimethylsilyl.
The compounds of Table 4 may be prepared according to the method described in Example 1C using the appropriate hydroxy aromatic compound and the appropriate polar solvent.
TABLE 4 ______________________________________ ##STR22## (II) Ex. Ar mp (°C.) ______________________________________ 201 2-naphthyl 202 1-naphthyl 203 2-quinolinyl 204 4-quinolinyl 205 2-pyridyl 206 3-pyridyl 207 4-pyridyl 208 2-pyrimidyl 209 2-furyl 210 2-thienyl ______________________________________
The compounds of Table 5 may be prepared according to the method of Example 1C using the appropriate 4-methanesulfonyloxypiperidine derivative.
TABLE 5
______________________________________
##STR23## (II)
Ex. TR Notes
______________________________________
211 1-CH.sub.3
212 2-CH.sub.3 (a)
213 2,2-Cl.sub.2 -1-CH.sub.3
(b)
214 2,2-(CH.sub.3).sub.2 -3-(CHC(CH.sub.3).sub.2)
215 2,3(CH.sub.3).sub.2 -3-(CHCCl.sub.2)
216 2,2-Cl.sub.2
217 2-F
218 2-Cl
219 1-OH
220 2,2,3,3-(CH.sub.3).sub.4
______________________________________
Footnotes for Table 5
(a) .sup.1 H-NMR(CDCl.sub.3, 300 MHz): 6.95(t, 2H, J=7), 6.8(dd, 2H,
J=7, 6), 4.65(br d, 1H, J=8), 4.25(br d, 1H, J=8),
3.9-3.7(m, 2H), 3.15(br t, 1H, J=8), 2.65(br t, 1H, J=8),
2.15-1.8(m, 3H), 1.5-1.1(m, 5H), 1.15(d, 3H, J=7),
0.65-0.45(m, 1H); HRMS: Calcd for C.sub.17 H.sub.22 FNO.sub.2 :
291.1634;
Found: 291.1636.
(b) .sup.1 H-NMR(CDCl.sub.3, 300 MHz): 7.05-6.9(m, 2H), 6.9-6.8(m,
2H), 4.65(br t, 1H, J=10), 3.95(br t, 1H, J=10), 3.9-3.75(m,
2H), 3.35-3.2(m, 1H), 2.8-2.65(m, 1H), 2.2-2.0(m, 2H),
2.0-1.9(m, 1H), 1.7-1.2(m, 4H), 1.55(d, 3H, J=7); HRMS:
Calcd for C.sub.17 H.sub.20 Cl.sub.2 FNO.sub.2 : 359.0855; Found:
359.0860.
Compounds of Formula (I) are exemplified in the following Tables 6-17.
The compounds of Tables 6, 7, 8, 9 and 10 may be prepared employing the procedure described for Example 1D with the appropriate 1-(cyclopropylcarbonyl)piperidine derivative (Examples 2-220) and the appropriate reducing agent.
TABLE 6
______________________________________
##STR24##
Ex. R mp (°C.)
______________________________________
1D 4-F (a)
221 4-Cl (b)
222 4-CH.sub.3 O 37-39(c)
223 H 54-56(d)
224 4-Br
225 4-I
226 4-NH.sub.2
227 4-(CH.sub.3).sub.2 N
228 4-NHC.sub.2 H.sub.5
229 4-CH.sub.3
230 4-C.sub.6 H.sub.5
81-83(e)
231 4-C.sub.2 H.sub.5 O
232 4-NHCH.sub.3
233 4-CH.sub.2 OH 120-121(f)
234 4-t-C.sub.4 H.sub.9
84-86(g)
235 4-SCH.sub.3 (h)
236 4-SO.sub.2 N(CH.sub.3).sub.2
237 4-CF.sub.3
238 4-CCl.sub.3
239 4-CH.sub.2 CF.sub.3
240 4-CH(OH)CH.sub.3 125-127(i)
241 4-CH.sub.2 CH.sub.3 F
242 4-SH
243 4-CH.sub.2 NH.sub.2
(j)
244 4-CH.sub.2 N(CH.sub.3).sub.2
245 4-CHCH.sub.2
246 3-Cl
247 3-Br
248 3-I
249 3-F
250 3-CH.sub.3 O
251 3-C.sub.2 H.sub.5 O
252 3-CH.sub.3
253 3-C.sub.2 H.sub.5
254 3-CH.sub.2 OH
255 3-CH(OH)CH.sub.3
256 3-CF.sub.3
257 3-CH.sub.2 CF.sub.3
258 3-CH(OH)CF.sub.3
259 3-CH.sub.2 CH.sub.2 F
260 3-CH.sub.2 NH.sub.2
261 3-CH.sub.2 N(CH.sub.3).sub.2
262 3-NHCH.sub.3
263 3-NHC.sub.2 H.sub.5
264 3-NH.sub.2
265 3-N(CH.sub.3).sub.2
266 3-SCH.sub.3
267 2-F
268 2-Br
269 2-Cl
270 2-I
271 2-CH.sub.3 O
272 2-CH.sub.3
273 2-CH.sub.2 OH
274 2-CH(OH)CH.sub.3
275 2-CF.sub.3
276 2-CH.sub.2 CF.sub.3
277 2-CH.sub.2 NH.sub.2
278 2-CH.sub.2 N(CH.sub.3).sub.2
279 2-NHCH.sub.3
280 2-NHC.sub.2 H.sub.5
281 2-NH.sub.2
282 2-SCH.sub.3
283 3,4-F.sub.2 (k)
284 3,4-Cl.sub.2
285 3,4-(CH.sub.3 O).sub.2
286 2,6-Br.sub.2 -4-CH.sub.3
287 2,6-Br.sub.2 -4-NH.sub.2
288 2,4-Cl.sub.2 -6-NH.sub.2
289 2,4-Cl.sub.2
290 3,5-Cl.sub.2
291 3-(C.sub.2 H.sub.5).sub.2 N
292 2,4-F.sub.2
293 2,3-F.sub.2
294 2,3-(CH.sub.3 O).sub.2
295 3,4-(CH.sub.3).sub.2
296 2,4-(CH.sub.3).sub.2
297 2,4-(NH.sub.2).sub.2
298 3-(OC.sub.2 H.sub.5)-4-(OCH.sub.3)
299 4-(OCH.sub.3)-3-(OC.sub.2 H.sub.5)
300 5-F-2-NH.sub.2
301 2-CH.sub.3 O-4-NH.sub.2
302 3-CH.sub.3 O-4-NH.sub.2
303 3-4-OCH.sub.2 O
304 3-CH.sub.3 -4-NH.sub.2
305 4-CH.sub.3 -3-NH.sub.2
306 2-CH.sub.3 -3-NH.sub.2
307 2-NH.sub.2 -3-CH.sub.3
308 F.sub.5 (l)
309 Br.sub.5
310 Cl.sub.5
311 2,3,5,6-F.sub.4
312 2,3,5,6-Cl.sub.4
313 2,4,5-F.sub.3
314 2,4,5-Cl.sub.3
315 2,4,5-Br.sub.3
316 3,4,5-(CH.sub.3 O).sub.3
(m)
______________________________________
Footnotes for Table 6
(a) .sup.1 H-NMR: 7.0-7.0-6.7(m, 4H), 3.7(d, 3H, J=7), 3.05(br d,
2H, J=10), 2.2(d, 2H, J=7), 2.0-1.6(m, 6H), 1.5-1.25(m,
2H), 0.95-0.75(m, 1H), 0.65-0.5(m, 2H), 0.1-0.0(m, 2H),
MS: 263.
(b) .sup.1 NMR(200 MHz, Cdcl.sub.3 -DMSO): 7.7(d, 2H, J=8), 7.35(d,
2H, J=8), 4.3-4.2(m, 2H), 3.6-3.4(m, 2H), 2.65(d, 2H, J=6),
2.5-2.1(m, 4H), 1.96-1.7(m, 2H), 1.4-1.2(m, 1H), 1.0-0.85(m,
2H), 0.6-0.5(m, 2H); HRMS: Calcd for C.sub.16 H.sub.21 ClNO:
279.1390; Found 279.1376.
(c) .sup.1 H-NMR(200 MHz, CDCl.sub.3 -DMSO): 7.15(s, 4H),
4.25-4.1(m, 2H), 4.2(s, 3H), 3.6-3.4(m, 2H), 2.65(d, 2H,
J=7), 2.55-2.1(m, 5H), 1.95-1.75(m, 2H), 1.4-1.25(m, 1H),
1.0-0.85(m, 2H), 0.6-0.45(m, 2H).
(d) Anal.: Calcd for C.sub.16 H.sub.23 NO: C, 78.26, H, 9.37, N, 5.71;
Found: C, 77.94, H, 9.49, N, 5.55.
(e) Anal.: Calcd for C.sub.22 H.sub.27 NO.0.125 H.sub.2 O: C, 81.67, H,
8.43, N,
4.33; Found: C, 81.86, 81.85, H, 8.64, 8.71, N, 4.13, 4.05.
(f) Anal.: Calcd for C.sub.17 H.sub.25 NO.sub.2.0.3 H.sub.2 O: C, 72.72,
H, 9.19, N,
4.99; Found: C, 72.98, 73.08, H, 9.04, 9.10, N, 4.97, 4.96.
(g) Anal.: Calcd for C.sub.20 H.sub.31 NO: C, 79.73, H, 10.30, N, 4.65;
Found: C, 79.71, H, 10.18, N, 4.72.
(h) .sup.1 H-NMR(CDCl.sub.3, 300 MHz): 7:15(d, 2H, J=8), 6.75(d, 2H,
J=8), 3.7(d, 2H, J=7), 3.05(br d, 2H, J=9), 2.25(s, 3H),
2.15(d, 2H, J=7), 2.0-1.6(m, 5H), 1.45-1.3(m, 2H),
0.9-0.7(m, 1H), 0.5-0.35(m, 2H), 0.1-0.0(m, 2H); HRMS:
Calcd for C.sub.17 H.sub.25 NOS: 291.1657; Found: 291.1653.
(i) Anal.: Calcd for C.sub.18 H.sub.27 NO.sub.2 : C, 74.96, H, 9.09, N,
4.85;
Found: C, 74.77, H, 9.38, N, 4.75.
(j) .sup.1 H-NMR(CDCl.sub.3, 300 MHz): 7.15(d, 2H, J= 8), 6.8(d, 2H,
J=8), 3.75(d, 2H, J=7), 2.9(br d, 2H, J=10), 2.1(d, 2H,
J=7), 1.9-1.5(m, 6H), 1.3-1.1(m, 3H), 0.85-0.7(m, 1H),
0.55-0.45(m, 2H), 0.1-0.0(m, 2H).
(k) .sup.1 H-NMR(CDCl.sub.3, 300 MHz): 6.95(q, 1H, J=8), 6.65-6.5(m,
1H), 6.5-6.4(m, 1H), 3.65(d, 2H, J=7), 3.05(br d, 2H,
J=10), 2.2(d, 2H, J=7), 2.0-1.8(m, 2H), 1.8-1.6(m, 3H),
1.5-1.3(m, 2H), 0.9-0.7(m, 1H), 0.65-0.5(m, 2H), 0.10-0.0(m,
2H); MS: 281.
(l) .sup.1 H-NMR(CDCl.sub.3): 6.15(s, 2H), 3.85(s, 6H), 3.8(s, 2H),
3.75(d, 3H, J=7), 3.15(br d, 2H, J=10), 2.3(d, 2H, J=7),
2.1-1.7(m, 5H), 1.65-1.4(m, 2H), 1.0-0.8(m, 1H), 0.6-0.45(m,
2H), 0.15-0.05(m, 2H), HRMS: Calcd for C.sub.19 H.sub.29 NO.sub.4 :
335.2096; Found: 335.2105.
(m) .sup.1 H-NMR(CDCl.sub.3, 200 MHz)): 4.0(d, 2H, J=7), 3.15(br d,
2H, J=10), 2.3(d, 2H, J=7), 2.05(br t, 2H, J=7) 1.9-1.7(m,
3H), 1.5-1.35(m, 2H), 0.95-0.85(m, 1H), 0.55-0.45(m, 2H),
0.15-0.05(m, 2H); HRMS: Calcd for C.sub.16 H.sub.18 F.sub. 5 NO:
335.1308;
Found: 335.1304.
TABLE 7
______________________________________
##STR25## (I)
Ex. Ar mp (°C.)
______________________________________
317 2-naphthyl 69-71(a)
318 1-naphthyl
319 2-4-dichloro-1-naphthyl
320 4-indolyl
321 4-indolyl
322 5-isoquinolinyl
323 4-pyridyl 53-54(b)
324 3-pyridyl
325 2-methyl-4-quinolinyl
326 4-quinolinyl 85-86(c)
327 5-quinolinyl
328 5-pyrimidyl
______________________________________
Footnotes for Table 7
(a) Anal.: Calcd for C.sub.20 H.sub.25 NO.0.25H.sub.2 O: C, 80.09, H,
8.58, N,
4.67; Found: C, 80.30, 80.40, H, 8.58, 8.65, N, 4.52, 4.70.
(b) Anal.: Calcd for C.sub.15 H.sub.22 N.sub.2 O.0.25H.sub.2 O: C, 71.82,
H, 8.84, N,
11.17; Found: C, 71.84, 71.86, H, 9.07, 9.07, N, 10.98, 11.06.
(c) Anal.: Calcd for C.sub.19 H.sub.24 N.sub.2 O.0.75H.sub.2 O: C, 73.63,
H, 8.29, N,
9.03; Found: C, 73.59, 73.86, H, 8.33, 8.33, N, 8.71, 8.77.
TABLE 8 ______________________________________ ##STR26## (I) Ex. R mp (°C.) ______________________________________ 329 4-F (a) 330 4-Cl 331 4-Br 332 4-I 333 H 334 4-CH.sub.3 O 335 4-C.sub.2 H.sub.5 O 336 4-TBDMSO 337 4-NH.sub.2 338 4-(CH.sub.3).sub.2 N 339 4-NHC.sub.2 H.sub.5 340 4-CH.sub.3 341 4-C.sub.2 H.sub.5 342 4-CH.sub.2 OH 343 4-CH(OH)CH.sub.3 344 4-CF.sub.3 345 4-CH.sub.2 346 4-CH.sub.2 N(CH.sub.3).sub.2 347 4-SCH.sub.3 348 3-F 349 3-Cl 350 3-Br 351 3-I 352 3-CH.sub.3 O 353 3-C.sub.2 H.sub.5 O 354 3-CH.sub.2 OH 355 3-CH(OH)CH.sub.3 356 3-CF.sub.3 357 3-CH.sub.2 NH.sub.2 358 3-CH.sub.2 N(CH.sub.3).sub.2 359 3-NH.sub.2 360 3-NHC.sub.2 H.sub.5 361 3-NHCH.sub.3 362 3-(CH.sub.3).sub.2 N 363 3-SCH.sub.3 364 2-F 365 2-Cl 366 2-Br 367 2-I 368 2-CH.sub.3 O 369 2-CH.sub.3 370 2-CH.sub.2 OH 371 2-CF.sub.3 372 2-CH.sub.2 NH.sub.2 373 2-NH.sub.2 374 3,4-F.sub.2 375 3,4-Cl.sub.2 376 3,4-(CH.sub.3 O).sub.2 377 2,4-Cl.sub.2 378 2,4-F.sub.2 379 2,4-(CH.sub.3 O).sub.2 380 3,5-F.sub.2 381 3,4-Cl.sub.2 382 3,4-(CH.sub.3).sub.2 383 2,4-(NH.sub.2).sub.2 384 3,4-(NH.sub.2).sub.2 385 4-(CH.sub.3 O)-3-NH.sub.2 386 3,4-OCH.sub.2 O 387 F.sub.5 388 Cl.sub.5 389 3,4,5-(CH.sub.3 O).sub.3 ______________________________________ Footnote for Table 8 (a) bp 115-137° C. (0.3 mm Hg); .sup.1 HNMR: 7.33-7.06(m, 2H), 7.03-6.97(m, 2H), 4.45(s, 2H), 3.32(d, 2H, J=6); HRMS: Calcd for C.sub.17 H.sub.24 FNO:277.1842; Found: 277.1829; Anal.: Calcd for C.sub.17 H.sub.2 FNO: C, 73.61, H, 8.72, N, 5.50; Found: C, 72.68, 72.51, H, 9.27, 8.98, N 4.66, 4.96.
TABLE 9 ______________________________________ ##STR27## (I) Ex. Ar mp (°C.) ______________________________________ 390 2-naphthyl 391 1-naphthyl 392 2-quinolinyl 393 4-quinolinyl 394 2-pyridyl 395 3-pyridyl 396 4-pyridyl 397 2-pyrimidyl 398 2-furyl 399 2-thienyl ______________________________________
TABLE 10
______________________________________
##STR28##
Ex. R mp (°C.)
______________________________________
400 1-CH.sub.3
401 2-CH.sub.3 (a)
402 2,2-Cl.sub.2 -1-CH.sub.3
(b)
403 2,2-(CH.sub.3).sub.2 -3-(CHC(CH.sub.3).sub.2)
404 2,2-(CH.sub.3).sub.2 -3(CHCCl.sub.2)
405 2,2-Cl.sub.2
406 2-F
407 2-Cl
408 1-OH
409 2,2,3,3-(CH.sub.3).sub.4
______________________________________
Footnotes for Table 10
(a) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 6.95(t, 2H, J=8), 6.8(dd, 2H,
J=8,6), 3.75(d, 2H, J=7), 3.2-3.0(m, 2H), 2.45(dd, 1H, J=9,6), 2.15(dd,
1H, J=9,7), 2.1-1.9(m, 2H), 1.9-1.7(m, 3H), 1.55-1.4(m, 2H), 1.05(d, 3H,
J=7), 1.65-1.45(m, 2H), 0.25(t, 2H, J=7); Calcd for C.sub.17 H.sub.24 FNO
277.1842; Found: 277.1818.
(b) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 7.0-6.9(m, 2H), 6.9-6.8(m, 2H),
3.75(d, 2H, J=7), 3.0-2.9(m, 2H), 2.55(dd, 2H, J=12,6), 2.1-1.95(m, 2H),
1.9-1.7(m, 4H), 1.4(s, 3H), 1.5-1.3(m, 1H), 1.25(s, 2H); HRMS: Calcd for
C.sub.17 H.sub.22 FCl.sub.2 NO: 345.1063; Found: 345.1064.
A solution of 1-(cyclopropylmethyl)-4-(4'-fluorophenoxymethyl)piperidine (250 mg, 0.95 mmol) in ether (5 mL) was stirred at room temperature. A 1 N hydrogen chloride-ether solution (5 mL) was added dropwise. The precipitate was filtered and washed with copious amounts of ether. Drying in at 60° C. afforded a white powder (200 mg): mp 162°-164° C.; 1 H-NMR (DMSO-d6): 10.6-10.2 (m, 1H), 7.35-6.85 (m 5H), 3.9 (d, 2H, J=7), 3.6-3.4 (m, 1H), 3.35-3.1 (m, 2H), 3.05-2.75 (m, 3H), 2.1-1.5 (m, 4H), 1.2-1.0 (m, 2H), 0.7-0.55 (m, 2H), 0.25-0.1 (m, 2H); Anal.: Calcd for C16 H23 FNO.HCl C, 63.88, H, 8.04, N, 4.66, F, 6.32, Cl, 11.79; Found: C, 64.08, H, 7.84, N, 4.58, F, 6.10, Cl, 11.96.
The compounds of Table 11 can be prepared using the process described in Example 410, employing the appropriate acid.
TABLE 11
______________________________________
##STR29## (I)
Ex. m R.sup.1 R.sup.2 HX mp (°C.)
______________________________________
410 0 4-F H HCl 162-164
411 0 4-Cl H HCl 145-146 (a)
412 0 4-CH.sub.3 O
H HCl 125-127 (b)
413 0 3,4,5-(CH.sub.3 O).sub.3
H HCl 113-114 (c)
414 0 4-CH.sub.2 OH
H HCl
415 0 H H HCl
416 1 F H HCl 123-125 (d)
417 1 4-CH.sub.3 O
H HCl
418 0 3-(CH.sub.3).sub.2 N
H HCl
419 3 F H HCl
420 0 4-CH.sub.3 S
H CHl 157-158 (e)
421 0 3,4-F.sub.2 H HCl 151-152 (f)
422 0 4-EtNH H HCl 130-133 (g)
423 0 F.sub.5 H HCl 173-174 (h)
424 0 4-F 2,2-Cl.sub.2 -1-CH.sub.3
maleate
156-157 (i)
425 0 4-F 2-CH.sub.3
fumarate
115-117 (j)
______________________________________
Footnotes for Table 11
(a) Anal.: Calcd for C.sub.16 H.sub.21 ClNO.HCl: C, 60.96, H, 7.03, N,
4.44, Cl, 22.49; Found: C, 60.85, H, 7.30, N, 4.43, Cl, 22.53.
(b) Anal.: Calcd for C.sub.17 H.sub.25 NO.sub.2.HCl.0.25H2O: C, 64.54, H,
8.44, N, 4.43, Cl, 11.20; Found: C, 64,53, 64.54, H, 8.43, 8.50, N, 4.32,
4.44, Cl, 11.58, 11.58.
(c) .sup.1 HNMR (DMSOd.sub.6): 10.9-10.6(m, 1H), 6.25(s, 2H), 5.5-5.1(m,
2H), 3.9-3.5(m, 5H), 2.75(s, 6H), 3.55(s, 3H), 3.1-2.8(m, 4H), 2.1-1.6(m,
4H), 1.2-1.0(m, 1H), 0.7-0.55(m, 2H), 0.45-0.3(m, 2H); Anal. Calcd for
C.sub.19 H.sub.29 NO.sub.4.1.3 HCl: C, 59.61, H, 7.97, N, 3.66, Cl, 12.04
Found: C, 59.31, 59.18, H, 8.10, 8.07, N, 3.50, 3.53, Cl, 11.67, 11.64.
(d) Anal.: Calcd for C.sub.17 H.sub.24 FNO.HCl: C, 65.06, H, 8.03, N,
4.46; Found: C, 65.16, 64.98, H, 8.18, 8.29, N, 4.29, 4.12.
(e) Anal.: Calcd for C.sub.17 H.sub.25 NOS.HCl: C, 62.27, H, 7.68, N,
4.27, S, 9.78, Cl, 10.81; Found: C, 62.30, H, 7.91, N, 4.17, S, 9.59, Cl,
10.83.
(f) Anal.: Calcd for C.sub.16 H.sub.21 F.sub.2 NO.HCl: C, 60.47, H, 6.66,
N. 4.41, F, 11.96, Cl, 11.16; Found: C, 60.43, H, 6.78, N, 4.25, F, 11.98
C, 10.91.
(g) Anal.: Calcd for C.sub.18 H.sub.28 N.sub.2 O.2HCl.0.5H.sub.2 O: C,
58.37, H, 8.44, N, 7.56; Found: C, 58.24, 58.50, H, 9.07, 8.74, N, 7.07,
6.96.
(h) Anal.: Calcd for C.sub.16 H.sub.18 F.sub.5 NO.HCl: C, 51.69, H, 5.15,
N, 3.76, F, 25.55, Cl, 9.54; Found: C, 51.60, H, 5.07, N, 3.97, F, 25.54,
Cl, 9.39.
(i) Anal.: Calcd for C.sub.17 H.sub.22 FCl.sub.2 NO.C.sub.4 H.sub.4
O.sub.4 : C, 54.56, H, 5.66, N, 3.03, Cl, 15.34, F, 4.11; Found C, 54.47,
H, 5.67, N, 3.02, Cl, 15.00, F, 4.10.
(j) Anal.: Calcd for C.sub.17 H.sub.24 FNO.C.sub.4 H.sub.4 O.sub.4 : C.
61.75, H, 6.91, N, 3.43, F, 4.65; Found: C, 62.28, 62.15, H, 7.03, 7.04,
N, 3.40, 3.38, F, 4.24, 4.09.
The compounds of Table 12 can be prepared using the process described in Example 410, employing the appropriate acid.
TABLE 12
______________________________________
##STR30## (I)
Ex. m Ar HX mp (°C.)
______________________________________
426 0 2-naphthyl HCl 206-208 (a)
427 0 4-pyridyl HCl
428 0 4-quinolinyl
HCl
______________________________________
Footnote for Table 12
(a) Anal.: Calcd for C.sub.20 H.sub.25 NO.HCl: C, 72.38, H, 7.90, N, 4.22
Cl, 10.68; Found: C, 72.27, H, 8.09, N, 4.14.
Example 429 describes an alternate procedure to prepare the product of Example 1.
(1) A solution of ethyl isonipecotate (65 g, 413 mmol) and pyridine (65.3 g, 66.8 mL, 826 mmol) in ether (500 mL) was stirred at about 0° C. under a nitrogen atmosphere. A solution of cyclopropyl-carboxylic acid chloride (43.2 g, 37.5 mL, 413 mmol) in ether (500 mL) was added dropwise over 30 minutes. The reaction mixture was stirred while warming gradually to room temperature over 21 hours, then it was poured onto water (1 L) and mixed. The layers were separated; the organic layer was washed once with a 1 N hydrochloric acid solution (1 L), then twice with a saturated sodium bicarbonate solution (1 L). The organic solution was dried over magnesium sulfate and filtered. Solvent was removed in vacuo to give a clear pale yellow liquid. Vacuum distillation (bp 140°-145° C., 0.4 mm Hg) afforded a clear colorless liquid (45 g, 48% yield): 1 H-NMR: 4.5- 4.25 (m, 1H), 4.15 (q, 2H, J=7), 3.35-3.05 (m, 1H), 2.96-2.7 (m, 1H), 2.65-2.45 (m, 1H), 2.0-1.85 (m, 2H), 1.75-1.5 (m, 3H), 1.25 (t, 3H, J=7), 1.0-0.9 (m, 2H), 0.75-0.6 (m, 2H); HRMS: Calcd for C12 H19 NO3 :225.1365; Found: 225.1365.
(2) Alternatively, this compound can be made as follows: Ethyl isonipecotate (48 mL, 0.31 mole), (bromomethyl)cyclopropane (85%, 50 g, 0.31 mole), and potassium carbonate (48 g, 0.35 mole) were stirred at room temperature in dry ethyl alcohol (500 mL) for 23 hours. The mixture was filtered through Celite®, rinsed with ethyl acetate and concentrated in vacuo. The resulting mixture was diluted with ethyl acetate (1 L), extracted with H2 O (2×250 mL), dried (MgSO4) and concentrated in vacuo. The crude product was distilled, bp 90°-115° C. at 0.8 mm Hg, to yield the product (33.8 g, 52%) as a colorless oil, which gave 1 H-NMR and MS data as listed above in Example 420 A (1).
(1) A solution of lithium aluminum hydride in tetrahydrofuran (1 M, 54.6 mL, 54.6 mmol) was added to tetrahydrofuran (100 mL) via syringe with stirring under a nitrogen atmosphere. This solution was cooled to 0° to 50° C. A solution of ethyl I-(cyclopropyl-methyl) piperidine-4-carboxylate (11.5 g, 55 mmol) in tetrahydrofuran (100 mL) w-as added dropwise over 15 minutes. The reaction mixture was heated to reflux temperature and stirred for 4 hours. The mixture was cooled to ambient temperature and ethyl acetate (100 mL) was added dropwise, followed by water (20 mL). The resulting suspension was filtered through Celite®. The filtrate was concentrated in vacuo. Vacuum distillation (bp 100° C., 0.1 mm Hg) afforded the product (6.15 g): 1 H-NMR:3.5 (d, 2H, J=7), 3.1 (d, 2H, J=7), 2.4 (d, 2H, J=7), 2.1-1.6 (m, 6 H), 1.55-1.45 (m, 3H), 0.95-0.85 (m, 1H), 0.55-0.45 (m, 2H), 0.25-0.15 (m, 2H); HRMS: Calcd for C10 H19 NO:169.1467; Found: 169.1467.
(2) Alternatively, this compound can be made as follows: Lithium aluminum hydride (8.55 g, 0.225 mole) was added portionwise over 1 hour to az 0° C. solution of the ester from Step A above (47.6 g, 0.225 mole) in dry Et2 O (500 mL). After 1.5 hours, the reaction was carefully quenched with H2 O (100 mL), then filtered through Celite® and rinsed with Et2 O. The filtrate was diluted to 1 L total volume with Et2 O, and the phases were separated. The organic phase was extracted with brine, dried (MgSO4), and concentrated in vacuo. The crude product was distilled, bp 108°-127° C. at 1.2 mm Hg, to yield the product as a colorless oil (29.3 g, 77%), which gave 1 H-NMR and MS data as listed above in Example 420 B (1).
A solution of 4-fluorophenol (4.08 g, 36.4 mmol), 1-(cyclopropylmethyl)-4-hydroxymethyl-piperidine (6.15 g, 36.4 mmol) from Step B (1) or (2), and triphenylphosphine (14.43 g, 55 mmol) in benzene (100 mL) was stirred with ice-water bath cooling. Diethyl azodicarboxylate (9.58 g, 8.7 mL, 55 mmol) was added dropwise via syringe. The reaction mixture was heated to reflux and stirred for about 72 hour. The mixture was cooled to ambient temperature and solvent was removed in vacuo. The residue was dissolved in ethyl acetate (200 mL), and the organic solution was washed twice with water (100 mL) then twice with a 2 N sodium hydroxide solution (100 mL). Drying over magnesium sulfate, filtration and removal of solvent in vacuo gave a solid. Column chromatography using a gradient elution system (chloroform:methanol::95:5 to 4:1) afforded the product 740 mg, 8% yield, mp 34°-36° C.) which gave 1 H-NMR and MS data identical to that for the product from Example 1D.
The compounds of Table 13 may be prepared using the procedure described for Example 429, employing the appropriate phenol.
TABLE 13 ______________________________________ ##STR31## (I) Ex. R mp (°C.) ______________________________________ 429-C 4-F 34-36 430 4-NO.sub.2 68-70 431 4-CO.sub.2 CH.sub.3 432 4-CON(CH.sub.3).sub.2 433 4-CN 109-111 (a) ______________________________________ Footnote for Table 13 (a) See also Example 515
Example 434 and subsequent examples describe the preparation of additional compounds of formula (I) (where X=CO or CHOH)
A solution of di-isopropylamine (4.44 g, 6.16 mL, 44 mmol) in anhydrous tetrahydrofuran (50 mL) was cooled to about 0° C. with stirring in a flame-dried flask under a nitrogen atmosphere. A solution of n-butyl lithium in hexane (2.5 M, 17.6 mL, 44 mmol) was added dropwise, then the reaction mixture was stirred at about 0° C. for about 15 minutes. A solution of 4-picoline (3.92 g, 40 mmol) in anhydrous tetrahydrofuran (50 mL) was added dropwise, then the reaction mixture was stirred at about 0° C. for about 15 minutes.
A solution of ethyl 4-fluorobenzoate (6.73 g, 5.87 mL, 40 mmol) in tetrahydrofuran (100 mL) was stirred at about 0° C. under a nitrogen atmosphere. The pyridinemethyl lithium solution, prepared above was added dropwise via a canula. The reaction mixture was then stirred while being warmed to ambient temperature for about 3 hours. The reaction mixture was then poured onto a 2 N sodium hydroxide solution (200 mL) and extracted with ethyl acetate three times. The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo.
Column chromatography of the residue with ethyl acetate gave the product, a yellow solid (1.0 g, Rf =0.2): mp 90°-93° C.; 1 H-NMR: 8.65-8.5 (m, 2H) , 8.05 (dd, 2H, J=8,6), 7.25-7.1 (m, 4H), 4.3 (s, 2H); MS:215; IR (KBr): 1684(s), 1596(s), 1505(m), 1417(m).
The column was eluted with ethyl acetate-methanol (4:1) to give, after removal of solvent in vacuo, a glassy solid, 4-fluorophenyl bis-(4-pyridylmethyl) methanol (1.1 g):mp 35°-36° C.; 1 H-NMR: 8.2 (d, 4H, J=6), 7.25 (dd, 2H, J=8,6), 7.0 (dd, 2H, J=7), 6.85 (d, 2H, J=6), 3.8-3.6 (m, 1H), 3.2 (q, 4H, J=10); MS:308; IR(KBr):3420 (br, s), 2928 (m), 1603 (s), 1560 (m), 1510 (s), 1419 (s); Anal.: Calcd for C19 H17 FNO.0.5,H2 O: C, 71.91, H, 5.72, N, 8.83; Found: C, 71.75, 72.00, H, 5.60, 5.64, N, 8.44, 8.61.
Alternatively, Step 434 A(2) may be used to make an appropriate intermediate.
A solution of sodium bis(trimethylsilylamide) in tetrahydrofuran (1 M, 400 mL, 0.4 mol) was cooled to about 0° C. with stirring under a nitrogen atmosphere. A solution of 4-picoline (37.25 g, 38.9 mL, 0.4 mol) in anhydrous tetrahydrofuran (560 mL) was added dropwise over 30 minutes. The reaction mixture was stirred at 0°-10° C. for 30 minutes.
A solution of ethyl 4-fluorobenzoate (33.6 g, 29.3 mL, 0.2 mol) in anhydrous tetrahydrofuran (400 mL) was cooled to about 0° C. with stirring under a nitrogen atmosphere. The above solution of 4-pyridinemethyl sodium was added dropwise via an additional funnel such that the internal temperature did not exceed 15° C. The reaction mixture was then stirred at ambient temperature for about 3 hours. The reaction mixture was poured onto water (1 L) and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. Vacuum distillation (bp 140° C., 0.1 mm Hg) gave the product (25.3 g), which solidified on cooling and which was identical in all respects to the product from Example 434 A(1).
A mixture of 1-(4'-fluorophenyl)-2-(4'-pyridyl)ethanone from Step A(1) or A(2) above (5 g, 23.3 mmol) and bromomethyl cyclopropane (18.8 g, 13.5 mL, 140 mmol) was stirred at reflux temperature under a nitrogen atmosphere for about 1 hour. A pale yellow solid formed upon cooling to ambient temperature. Filtration and trituration with copious amounts of ether afforded a pale yellow solid:1 H-NMR: 9.45 (d, 2H, J=6), 8.35-8.0 (m, 4H), 7.2 (br t, 2H, J=7), 5.0-4.8 (m, 4H), 1.65-1.4 (m, 1H), 0.85-0.65 (m, 4H).
Platinum dioxide (1 g) was suspended in degassed ethanol (100 mL) and this suspension was stirred under a hydrogen atmosphere until hydrogen uptake ceased. A solution of 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoethyl)pyridinium bromide from Step B above, (7.9 g) in degassed ethanol (200 mL) was added and the mixture was stirred under a hydrogen atmosphere. After the theoretical amount of hydrogen had been taken up, the suspension was filtered through Celite®. Solvent was removed in vacuo to give the product as its hydrobromide salt, a white solid.
This solid was dissolved in water; the solution was basified with a 2 N sodium hydroxide solution, then extracted with chloroform three times. The combined organic layers were dried over magnesium sulfate and filtered. Solvent was removed in vacuo. Column chromatography (chloroform:methanol::9:1) gave the product, a pale yellow solid (Rf =0.25, 2.83 g): mp 73°-75° C.; IR (KBr): 3072 (w) , 3006 (w) , 2995 (w) , 2943 (s) , 2903 (s), 2840 (w), 2806 (w), 1679 (s), 1594 (s), 1504 (s), 1462 (s), 1448 (w), 1427 (w), 1410 (s); 1 H-NMR: 8.0 (dd, 2H, J=8,6), 7.15 (br t, 2H, J=8), 3.1 (br d, 2H, J=9), 2.9 (d, 2H, J=7), 2.35 (d, 2H, J=7), 2.1-1.6 (m, 6H), 1.55-1.35 (m, 2H), 1.0-0.8 (m, 1H), 0.65-0.4 (m, 2H), 0.25-0.0 (m, 2H); MS:275; Anal.: Calcd for C17 H22 FNO.O.25,H2 O: C, 72.96, H, 8.10, N, 5.00, F, 6.78; Found: C, 73.16, 72.99, H, 8.10, 8.06, N, 5.11, 5.13, F, 6.58, 6.52.
The compounds of Table 14 may be prepared using, in sequence, the procedures described in Examples 434 A(1) or A(2), B and C starting with the appropriate benzoate ester.
TABLE 14
______________________________________
##STR32##
Ex. R Salt mp (°C.)
______________________________________
434 4-F 73-75
435 4-Cl HBr 154-155 (a)
436 4-Br
437 4-I
438 H
439 4-N(CH.sub.3).sub.2 104-106 (b)
440 4-NCOCH.sub.3
441 4-NH.sub.2
442 4-OCH.sub.3 HBr 167-168 (c)
443 4-OTBDMS (d)
444 4-OC.sub.2 H.sub.5
445 4-SCH.sub.3
446 4-SC.sub.2 H.sub.5
447 4-CH.sub.2 NH.sub.2
448 3,5-(CF.sub.3).sub.2
449 4-CH.sub.3
450 4-C.sub.2 H.sub.5
451 4-CF.sub.3 35-36 (e)
452 3-Cl
453 2-Cl
454 3-Br
455 2-Br
456 3-I
457 2-I
458 3-N(CH.sub.3).sub.2
459 3-NHCOCH.sub.3
460 3-NH.sub.2
461 3-OCH.sub.3
462 3-OTBDMS
463 3-OC.sub.2 H.sub.5
464 3-SCH.sub.3
465 3-CH.sub.2 NH.sub.2
466 3-CH.sub.2 N(CH.sub.3).sub.2
467 3-CF.sub.3
468 2-Cl-5-Br
469 3-Br-4-CH.sub.3
470 4-t-C.sub.4 H.sub.9 O
471 4-t-C.sub.4 H.sub.9
HBr 142-144 (f)
472 2-Cl-4-F
473 3-Cl-4-F
474 3-Cl-4-OTBDMS
475 4-Cl-2-OCH.sub.3
476 3-Cl-4-CH.sub.3
477 2-Cl-5(CH.sub.3 S)
478 2-Cl-4-(NH.sub.2)
479 4-Cl-3-NH.sub.2
480 3,5-Br.sub.2 -4-OTBDMS
481 3,4-Cl.sub.2
482 2,4-Cl.sub.2
483 3,5-Cl.sub.2
484 2,5-Cl.sub.2
485 3,5-Cl.sub.2 -4-OTBDMS
486 3,4-(OC.sub.2 H.sub.5).sub.2
487 3,4-(OCH.sub.3).sub.2
488 3,4-(OCH.sub.3).sub.2
489 4-(C.sub.2 H.sub.5).sub.2 N
490 3,4-F.sub.2
491 2,4-F.sub.2
492 3,5-F.sub.2
493 3,4-(CH.sub.3).sub.2
494 3,5-(CH.sub.3).sub.2
495 3,5-(NH.sub.2).sub.2
496 3-CH.sub.3 O-4NH.sub.2
497 F.sub.5
498 Cl.sub.5
499 2,3,4,5-F.sub.4
500 2,3,5-Cl.sub.2
501 2,3,4-F.sub.3
502 2,4,5-F.sub.3
503 4-C.sub.6 H.sub.5
HBr 233-234 (g)
______________________________________
Footnotes for Table 14
(a) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 7.88(d, 2H, J=8), 7.45(d, 2H, J=8)
3.77-3.68(m, 2H), 3.02(d, 2H, J=7), 2.90(d, 2H, J=8), 2.85-2.71(m, 2H),
2.40-1.97(m, 5H), 1.59(br m, 1H), 1.40-1.30(m, 1H), 0.85-0.78(m, 2H),
0.48-0.40(m, 2H); Anal.: Calcd for C.sub.17 H.sub.22 ClNO.HBr: C, 54.78,
H, 6.22, N, 3.76; Found: C, 54.50, H, 6.21, N, 3.85.
(b) .sup.1 HNMR (CDCl.sub.3 , 300 MHz): 7.9(d, 2H, J=9), 6.65(d, 2H, J=9)
3.2(br d, 2H, J=11), 3.1(s, 6H), 2.85(d, 2H, J=7), 2.4(d, 2H, J=7),
2.3-1.95(m, 4H), 1.9-1.7(m, 2H), 1.7-1.45(m, 2H), 1.1-0.9(m, 1H),
0.7-0.6(m, 2H), 0.3-0.1(m, 2H), HRMS: Calcd for C.sub.19 H.sub.28 N.sub.2
O: 300.2202; Found: 300.2218; Anal.: Calcd for C.sub.19 H.sub.28 N.sub.2
O.0.5.H.sub.2 O: C, 73.75, H, 9.28, N, 9.05; Found: C, 73.22, H, 9.05, N,
8.87.
(c) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 7.91(d, 2H, J=8), 6.94(d, 2H, J=8)
3.91(s, 3H), 3.76-3.68(m, 2H), 2.95(d, 2H, J=7), 2.90(d, 2H, J=7),
2.85-2.75(m, 2H), 2.40-2.15(m, 3H), 2.05-1.95(m, 2H), 1.60(br m, 1H),
1.40-1.31(m, 1H), 0.84-0.77(m, 2H), 0.50-0.43(m, 2H); Anal.: Calcd for
C.sub.18 H.sub.25 NO.sub.2.HBr: C, 58.70, H, 7.12, N, 3.80; Found: C,
58.75, 58.54, H, 7.19, 7.14, N, 3.81, 3.81.
(d) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 7.85(br d, 2H, J=8), 6.85(br d, 2H
J=8), 3.05(br d, 2H, J=10), 2.85(d, 2H, J=7), 2.25(d, 2H, J=7), 2.1(br t,
3H, J=7), 1.85-1.7(m, 2H), 1.5-1.3(m, 2H), 1.0(s, 9H), 0.95-0.8(m, 2H),
0.55-0.45(m, 2H), 0.25(s, 6H), 0.15-0.05(m, 2H); HRMS: Calcd for C.sub.23
H.sub.37 NO.sub.2 Si: 387.2594; Found: 387.2591.
(e) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 8.05(d, 2H, J=8), 7.75(d, 2H, J=8)
3.1(br d, 2H, J=10), 2.95(d, 2H, J=7), 2.3(d, 2H, J=7), 2.2-1.95(m, 3H),
1.9-1.7(m, 2H), 2.6-2.35(m, 2H), 1.0-0.8(m, 1H), 0.6-0.45(m, 2H),
0.2-0.05(m, 2H); HRMS: Calcd for C.sub.18 H.sub.22 F.sub.3 NO:325.1676;
Found: 325.1652; Anal.: Calcd for C.sub.18 H.sub.22 F.sub.2
NO.0.25.H.sub.2 O: C, 65.54, H, 6.87, N, 4.24, F, 17.27; Found: C, 65.57,
65.52, H, 6.89, 6.89, N, 4.31, 4.36, F, 17.34.
(f) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 7.89(d, 2H, J=8), 7.49(d, 2H, J=8)
3.77-3.69(m, 2H), 3.02(d, 2H, J=6), 2.90(d, 2H, J=8), 2.84-1.30(m, 9H),
1.35(s, 9H), 0.85-0.78(m, 2H), 0.48-0.41(m, 2H); HRMS: Calcd for C.sub.21
H.sub.21 NO: 313.2406; Found: 313.2405; Anal.: Calcd for C.sub.21 H.sub.3
NO.HBr.0.5 H.sub.2 O: C, 62.52, H, 8.25, N, 3.47; Found: C, 62.70, 62.47,
H, 8.00, 7.94, H, 3.34, 3.33.
(g) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 8.03(d, 2H, J=8), 7.70(d, 2H, J=8)
7.65-7.40(m, 5H), 3.78-3.69(m, 2H), 3.08(d, 2H, J=7), 2.90(d, 2H, J=8),
2.87-2.75(m, 2H), 2.43-1.98(m, 5H), 1.58(br m, 1H), 1.43-1.32(m, 1H),
0.95-0.87(m, 2H), 0.49-0.41(m, 2H); Anal.: Calcd for C.sub.23 H.sub.25
NO.HBr: C, 66.66, H, 6.81, N, 3.38; Found; C, 66.23, 66.22, H, 6.86, 7.08
N, 3.41, 3.42.
A mixture of 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2-oxoethyl)piperidine (24.1 g, 87.6 mmol), a hydrobromic acid solution (0.4 M, 62 ml) and ethanol (50 mL) was stirred with gentle heating until- all solid dissolved. Solvent was removed in vacuo with gentle heating to give a white solid. The solid was suspended in a 2-propanol and mixed; again solvent was removed in vacuo with gentle heating to give a white solid. Trituration with ether and filtration gave the product. Drying in vacuo at about 60° C. in a drying oven gave a white powder. (25.9 g): mp 141°-143° C.; IR (KBr) 3067 (w), 3038 (w), 2986 (m), 2939 (s), 2921 (s), 2702 (s), 2645 (s), 2592 (s), 2567 (s), 2520 (s), 1683 (s), 1601 (s), 1509 (s), 1470 (m), 1459 (s), 1436 (s), 1412 (s); 1 H-NMR (DMSO-d6): 9.5-9.2 (m, 1H), 8.2-8.0 (br t, 2H, J=7), 7.4 (br t, 2H, J=7), 3.6-2.8 (m, 8H), 2.25-1.4 (m, 4H), 1.25-1.0 (m, 1H), 0.7-0.5 (m, 2H), 0.45-0.3 (m, 2H); Anal.: Calcd for C17 H22 FNO.HBr: C, 57.31, H, 6.51, N, 3.93, F, 5.33, Br, 22.43; Found: C, 57.57, H, 6.65, N, 3.86, F, 5.15, Br, 22.16.
The compounds of Table 15 may be prepared by the procedure for Example 504 using the appropriate acid.
TABLE 15
______________________________________
##STR33## (I)
Ex. R Salt mp (°C.)
______________________________________
504 4F HBr 141-143
505 4-CF.sub.3 HCl 140-142 (a)
506 4-N(CH.sub.3).sub.2
HBr 113-115 (b)
______________________________________
Footnotes for Table 15
(a) Anal.: Calcd for C.sub.18 H.sub.22 F.sub.3 NO.HCl.0.5H.sub.2 O: C,
58.29, H, 6.52, N, 3.77, F, 15.27, Cl, 9.56; Found: C, 58.49, 58.22, H,
6.34, 6.33, N, 3.84, 3.80, F, 15.24, 15.32, Cl, 9.50, 9.28.
(b) Anal.: Calcd for C.sub.19 H.sub.28 N.sub.2 O.2HBr.0.5H.sub.2 O: C,
48.42, H, 6.63, N, 5.94, Br, 33.91; Found: C, 48.83, 48.73, H, 6.89, 6.76
N, 5.65, 5.44, Br, 33.10, 33.27.
EXAMPLE 507
1-(Cyclopropylmethyl)-4-(2'-(4"-t-butyldimethylsilyloxyphenyl)-2'-oxoethyl)piperidine (from Example 443 above) (250 mg, 1.02 mmol) was reacted with a solution of tetra-n-butylammonium fluoride in tetrahydrofuran (1 M, 3 mL, 3 mmol) for about 14.5 hours. Solvent was removed in vacuo. The residue was dissolved in water; a 1 N hydrochloric acid solution was added until pH=7. Three extractions with ethyl acetate, drying over magnesium sulfate, filtration and concentration in vacuo gave a light brown oil.
The oil was dissolved in ether-ethanol (5 mL, 1:1 (v/v)). A solution of hydrogen chloride in ether (1 M, 5 mL, 5 mmol) was added with stirring. Solvent was removed in vacuo; the residue was triturated with acetone and filtered. Drying in vacuo gave a white solid (25 mg) : mp 209°-211° C.; NMR (DMSO-d6, 300 MHz) 10.4 (s, 1H), 7.9 (d, 2H, J=8), 6.85 (d, 2H, J=8), 3.55-3.45 (m, 1H), 3.0-2.8 (m, 1H), 1.95-1.85 (m, 2H), 1.7-1.5 (m, 2H), 1.15-1.0 (m, 1H), 0.7-0.6 (m, 2H), 0.45-0.35 (m, 2H); HRMS: Calcd for C17 H23 NO2 :273.1729; Found: 273.1727.
Sodium hydride (50% in oil, 0.48 g, 10 mmol) was washed with hexanes twice (decanting the solvent each time) and suspended in N,N-dimethylformamide (20 mL) with stirring under a nitrogen atmosphere. A solution of 1-(cyclopropylmethyl)-4-(hydroxy-methyl)piperidine (Example 429B) (1.6 g, 9.5 mmol) in N,N-dimethylformamide (10 mL) was added dropwise. Gas evolution occurred. 4-Fluorobenzonitrile (1.21 g, 10 mmol-) was added, then the reaction mixture was stirred at 100° C. for 17 hours. Water was added. The solvent was distilled in vacuo. The residue was taken up in water, basified with a 1 N sodium hydroxide solution and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO4 and filtered. Solvent was removed in vacuo to give a brown oil.
Column chromatography (chloroform: methanol::9:1) gave a brown oil, after removal of solvent in vacuo. The oil was crystallized from ether-hexanes and filtered. Drying in vacuo afforded the product, a white powder (1.23 g) : mp 109°-111° C.; IR (KBr) 3074 (w), 2997 (m), 2962 (w), 2939 (s), 2918 (s), 2883 (s), 2826 (s), 2779 (m), 2232 (s), 1607 (s), 1574 (m), 1511 (s); NMR CDCl3, 300 MHz): 7.75 (d, 2H, J=8), 6.9 (d, 2H, J=8), 3.85 (d, 2H, J=7), 3.1 (br d, 2H, J=10), 2.25 (d, 2H, J=7), 2.0 (td, 2H, J=8), 1.9-1.75 (m, 3H), 1.5-1.35 (m, 2H), 0.9-0.8 (m, 1H), 0.55-0.45 (m 2, H), 0.15-0.05 (m, 2H); HRMS: Calcd for C17 H22 N2 O: 270.1732; Found: 270.1727; Anal.: Calcd for C17 H22 N2 O: C, 75.52, H, 8.20, N, 10.36; Found: C, 75.36, H, 8.35, N, 10.27.
The compounds in Table 16 may be prepared by the method described in Examples 1, 429 or 508 using the appropriate benzene derivative.
TABLE 16
______________________________________
##STR34## (I)
Ex. R X p Salt mp (°C.)
______________________________________
509 4-F S 1 (a)
510 4-F NMe 1
511 4-F CHOH 1 114-116 (b)
512 4-NO.sub.2 O 1 68-70 (c)
513 4-F NH 1
514 1-tetrazole O 1
515 4-CN O 1 109-111 (d)
516 4-COCH.sub.3 O 1 41-43 (e)
517 4-SO.sub.2 (OCH.sub.2 C.sub.6 H.sub.5)
O 1
518 4-CO.sub.2 CH.sub.2 Ph
O 1
519 4-CHO O 1
520 4-SO.sub.2 N(CH.sub.3).sub.2
O 1 118-119 (f)
521 4-F O 3
522 4-F CO 0
523 4-F SO 1 (g)
524 4-F SO.sub.2
1 73 (h)
525 4-F CO 2 HBr 108-109 (i)
526 4-F O 2 (j)
527 4-F O 2 fumarate
124-126 (k)
______________________________________
Footnotes for Table 16
(a) .sup.1 HNMR (CDCl.sub.3, 200 MHz): 7.3(dd, 2H, J=8,6), 7.0(t, 2H,
J=8), 3.1(br d, 2H, J=10), 2.8(d, 2H, J=7), 2.15(d, 2H, J=7), 2.0-1.8(m,
4H), 1.6-1.3(m, 3H), 0.95-0.8(m, 1H), 0.6-0.45(m, 2H), 0.15-0.05(m, 2H);
HRMS: Calcd for C.sub.16 H.sub.22 FNS: 279.1457; Found: 279.1460.
(b) Anal.: Calcd for C.sub.17 H.sub.24 FNO: C, 73.61, H, 8.72, N, 5.05, F
6.84; Found: C, 72.64, 72.96, H, 8.77, 8.61, N, 5.00, 4.92, F, 6.86.
(c) Anal.: Calcd for C.sub.16 H.sub.22 N.sub.2 O.sub.3.0.75H.sub.2 O: C,
63.26, H, 7.74, N, 9.22; Found: C, 63.14, 63.10, H, 7,40, 7.39, N, 9.35,
9.28.
(d) Anal.: Calcd for C.sub.17 H.sub.22 N.sub.2 O: C, 75.52, H, 8.20, N,
10.36; Found: C, 75.36, H, 8.35, N, 10.27. (See also Example 433).
(e) Anal.: Calcd for C.sub.18 H.sub.25 NO.sub.2 : C, 75.23, H, 8.77, N,
4.87; Found: C, 75.10, H, 8.87, N, 4.76.
(f) Anal.: Calcd for C.sub.18 H.sub.22 N.sub.2 O.sub.3 S: C, 61.33, H,
8.01, N, 7.95, S, 9.10; Found: C, 60.64, 60.64, H, 7.98, 7.94, N, 7.63,
7.64, S, 9.03.
(g) Anal.: Calcd for C.sub.16 H.sub.22 FNO.sub.2 S: C, 61.71, H, 7.12, N,
4.49, F, 6.10, S, 10.30; Found: C, 61.57, H, 7.26, N, 4.39, F, 6.40, S,
10.36.
(h) .sup.1 HNMR (CDCl.sub.3, 200 MHz): 7.65(dd, 2H, J=7,2), 7.25(dd, 2H,
J=8,2), 3.1(br t, 2H, J=9), 2.85(dd, 1H, J=10,2), 2.5(dd, 1H, J=10,8),
2.4-2.2(m, 2H), 2.15-1.9(m, 5H), 1.8-1.7(m, 1H), 1.55-1.4(m, 2H),
0.9-0.8(m, 1H), 0.6-0.45(m, 2H), 0.15-0.05(m, 2H); HRMS: Calcd for
C.sub.16 H.sub.22 FNOS: 295.1406; Found: 295.1409.
(i) Anal.: C.sub.18 H.sub.24 FNO.HBR: C, 58.38, H, 6.53, N, 3.78, F, 5.13
Br, 21.57; C, 58.13, 58.35, H, 6.51, 6.38, N, 3.70, 3.61, F, 4.95, 4.93,
Br, 21.59.
(j) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 6.9(br t, 2H, J=8), 6.75(dd, 2H,
J=8,6), 3.7(d, 2H, J=7), 2.9(br d, 2H, J=9), 2.5-2.35(m, 2H), 2.0-1.85(m,
2H), 1.85-1.65(m, 3H), 1.5-1.3(m, 4H), 0.7-0.5(m, 1H), 0.45-0.3(m, 2H),
0.1-0.0(m, 2H); HRMS: Calcd for C.sub.17 H.sub.24 FNO: 277.1842; Found:
277.1837.
(k) Anal.: Calcd for C.sub.17 H.sub.24 FNO.C.sub.4 H.sub.4 O.sub.4 : C,
64.11, H, 7.17, N, 3.56, F, 4.82; Found: C, 64.05, 64.30, H, 7.30, 7.41,
N, 3.89, 3.90, F, 4.83, 4.85.
The compounds in Table 17 may be prepared by the method described in Example 1C using the appropriate hydroxy aromatic compound.
TABLE 17
______________________________________
##STR35## (I)
Ex. R X n mp (°C.)
______________________________________
528 4-piperidinyl O 1
529 4-C.sub.6 H.sub.5
O 1
530 4-C.sub.6 H.sub.5 O
O 1 62-63 (a)
531 4-C.sub.6 H.sub.5 S
O 1
532 4-(4'-FC.sub.6 H.sub.4)
O 1 81-83 (b)
533 4-(4'-CH.sub.3 OC.sub.6 H.sub.4)
O 1 122-123 (c)
534 4-(4'-CH.sub.3 C.sub.6 H.sub.4)
O 1
535 4-(4'-CH.sub.3 SC.sub.6 H.sub.4)
O 1
536 4-(4'-CF.sub.3 C.sub.6 H.sub.4)
O 1
537 4-F O 0
______________________________________
Footnotes for Table 17
(a) Anal.: Calcd for C.sub.22 H.sub.27 NO.sub.2 : C, 78.30, H, 8.06, N,
4.15; Found: C, 78.20, H, 8.12, N, 4.04.
(b) Anal.: Calcd for C.sub.22 H.sub.26 FNO: C, 77.84, H, 7.72, N, 4.13, F
5.60; Found: C, 77.71, 77.71, H, 7.78, 7.78, N, 3.93, 3.93, F, 3.77, 3.60
(c) Anal.: Calcd for C.sub.23 H.sub.29 NO.sub.2.0.5H.sub.2 O: C, 76.62, H
8.39, N, 3.88; Found: C, 76.83, 76.86, H, 8.20, 8.17, N, 3.60, 3.58.
The compounds in Table 18 may be prepared by the methods described in Example 508 or 410, using the appropriate starting materials.
TABLE 18
______________________________________
##STR36##
Ex. Ar HX mp (°C.)
______________________________________
538 2-pyrimidyl (a)
539 2-pyrimidyl
HCl 151-152 (b)
540 2-pyridyl (c)
541 2-pyridyl HCl 176-178 (d)
______________________________________
Footnotes for Table 18
(a) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 8.45-8.35(m, 2H), 6.85-6.8(m, 1H),
4.1(d, 2H, J=7), 3.05(br d, 2H, J=10), 2.2(d, 2H, J=7), 2.0-1.7(m, 5H),
1.45-1.3(m, 2H), 0.9-0.75(m, 2H), 0.1-0.0(m, 2H).
(b) Anal.: Calcd for C.sub.14 H.sub.21 N.sub.3 O.1.3 HCl: C, 57.05, H,
7.62, N, 14.26, Cl, 15.64; Found: C, 56.18, 56.34, H, 7.51, 7.65, N,
13.95, 14.05, Cl, 15.05, 15.25.
(c) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 8.05-8.0(m, 1H), 7.5-7.35(m, 1H),
6.8-6.7(m, 1H), 6.65-6.55(m, 1H), 4.05(d, 2H, J=7), 3.05(br d, 2H, J=10),
2.2(d, 2H, J=7), 1.9(br t, 2H, J=9), 1.8-1.6(m, 3H), 1.5-1.3(m, 2H),
0.9-0.7(m, 1H), 0.5-0.35(m, 2H), 0.1-0.0(m, 2H); MS: 246.
(d) Anal.: Calcd for C.sub.15 H.sub.22 N.sub.2 O.1.5 HCl: C, 56.52, H,
7.43, N, 8.78, Cl, 16.68; Found: C, 56.37, 56.18, H, 7.77, 7.76, N, 8.61,
8.44, Cl, 19.76, 19.66.
A mixture of sodium cyanide (4.9 g, 100 mmol) and 1-(cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoethyl)piperidine (Example 434, 1.0 g, 3.6 mmol) in N,N-dimethylformamide (50 mL) was stirred at 120° C. for 26 h. The excess solvent was distilled in vacuo; the residue was dissolved in water and extracted three times with ethyl acetate. The combined organic layers were washed with water twice, dried over anhydrous magnesium sulfate and filtered. Solvent was removed in vacuo to give an oil.
Column chromatography (CHCl3 : MeOH::9:1) afforded the product, a solid (0.68 g. 67% yield): mp 107°-108° C.; Anal.: Calcd for C18 H22 N2 O .0.25H2 O: C, 75.38, H, 7.90, N, 9.76; Found: C, 75.13, 74.97, H, 7.87, 7.96, N, 9.65, 9.52.
Following the procedure of Example 542, sodium azide (6.5 g, 100 mmol) was reacted with the product of Example 434 (1.0 g, 3.6 mmol) to afford the title compound, a solid (0.35 g): mp 140-146 (dec); MS:272; Anal.: Calcd for C17 H22 N2 O.0.75H2 O: C, 71.42, H, 8.99, N, 9.80; Found: C, 71.06, 71.03, H, 8.58, 8.54, N, 9.98, 9.99.
A mixture of a 1 N NAOH solution (10 mL) and 1-(cyclopropylmethyl)-4-(4'-methylthiophenoxymethyl)piperidine, hydrochloride salt (Example 420, 0.5 g, 1.5 mmol) was stirred for 15 min and then extracted three times with ethyl acetate. The combined organic extracts were dried over anhydrous magnesium sulfate and filtered. Solvent was removed in vacuo. The residue was taken up in a mixture of methanol (10 mL) and water (10 mL). Sodium periodate (2.13 g, 10 mmol) was added; the resulting suspension was stirred for 22 h. The reaction mixture was diluted with 250 mL water, basified with 1 N NAOH solution and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and filtered. Solvent was removed in vacuo.
Column chromatography (CHCl3 :MeOH::9:1) of the residue afforded the title compound, a solid (0.29 g): mp 134°-135° C.; 1 H-NMR (CDCl3, 300 MHz) : 7.85 (d, 2H, J=8), 7.0 (d, 2H, J=8), 3.9 (d, 2H, J=7), 3.15 (br d, 2H, J=10), 3.05 (s, 3H), 2.3 (d, 2H, J=7), 2.1 (br t, 2H, J=7), 1.95-1.8 (m, 3H), 1.6-1.4 (m, 2H), 0.95-0.85 (m, 1H), 0.6-0.5 (m, 2H), 0.2-0.1 (m, 2H); HRMS: Calcd for C17 H25 NO3 S: 323.1555; Found: 323.1554.
1-(Cyclopropylmethyl)-4-(4'-fluorophenylthiomethyl)piperidine, hydrobromide salt (Example 509, hydrobromide salt, 1.0 g) was treated with a 1 N NaOH solution (50 mL); the mixture was extracted with ethyl acetate three times. The organic solution was dried over magnesium sulfate and filtered. Solvent was removed in vacuo.
The residue was reacted with sodium periodate (7.7 g, 36 mmol) in methanol (30 mL) and water (30 mL for 21.5 h). The reaction mixture was diluted with water (500 mL), basified with a 1 N NaOH solution and extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and filtered. Solvent was removed in vacuo.
Column chromatography (CHCl3 :MeOH::9:1) gave two products:
(1) (Cyclopropylmethyl)-4-(4'-fluorophenylsulfonylmethyl)piperidine (Example 545) Rf =0.3, 367 mg): mp 73° C.; 1 H-NMR (CDCl3, 200 MHz) : 7. 95 (dd, 2H, J=7, 2) , 7.25 (dd, 2H, J=8,2), 3.1-2.95 (m, 2H), 3.05 (d, 2H, J=7), 2.25 (d, 2H, J=7), 2.1-1.85 (m, 4H), 1.55-1.4 (m, 2H), 0.9-0.8 (m, 1H), 0.55-0.45 (m, 2H), 0.15-0.05 (m, 2H); Anal.: Calcd for C16 H22 FNO2 S: C, 61.71, H, 7.12, N, 4.49, F, 6.10, S, 10.30; Found: C, 61.57, H, 7.26, N, 9.39, F, 6.40, S, 10.36;
(2) 1-(cyclopropylmethyl)-4-(4'-fluorophenylsulfinylmethyl)piperidine (Example 546, Rf =0.17, 90 mg): 1 H-NMR (CDCl3, 200 MHz): 7.65, (dd, 2H, J=7,2), 7.25 (dd, 2H, J=8,2), 3.1 (br t, 2H, J=9), 2.85 (dd, 1H, J=10,2), 2.5 (dd, 1H, J=10,8), 2.4-2.2 (m, 2H), 2.15-1.9 (m, 5H), 1.8-1.7 (m, 1H), 1.55-1.4 (m, 2H), 0.9-0.8 (m, 1H), 0.6-0.45 (m, 2H), 0.15-0.05 (m, 2H); HRMS: Calcd for C16 H22 FNOS: 295.1406; Found: 295.1409.
1-(Cyclopropylmethyl)-4-(2'-(4"-fluorophenyl)-2'-oxoethyl)piperidine (Example 429, 1.0 g, 3.6 mmol) was mixed with dry tetrahydrofuran (10 mL). A solution of phenyl magnesium bromide in ether (3.0 M, 3 mL, 9 mmol) was added with stirring. The reaction mixture was stirred for 24 h; poured onto a saturated NH4 Cl solution and-extracted with ethyl acetate three times. The combined organic layers were dried over magnesium sulfate and filtered. Solvent was removed in vacuo. Trituration with ether-hexanes (1:9) and filtration afforded the title compound, a solid, which was dried in vacuo (0.9 g): mp 115°-116° C.; Anal.: Calcd for C23 H28 FNO: C, 77.36, H, 7.90, N, 3.92, F, 5.32; Found: C, 77.47, 77.41, H, 8.00, 7.92, N, 3.42, 3.52, F, 5.09.
Following the procedure described for Example 547, the compound of Example 429 (1.0 g, 3.6 mmol) was reacted a solution of 4-fluorophenylmagnesium bromide in tetrahydrofuran (1.0 M, 9 mL, 9 mmol) to give the title compound, a solid (1.1 g): mp 119°-121° C.; Anal.: Calcd for C23 H27 F2 NO.0.5H2 O: C, 72.60, H, 7.41, N, 3.68, F, 9.99; Found: C, 72.89, 72.84, H, 7.14, 7.21, N, 3.29, 3.24, F, 9.82, 9.67.
A solution of the compound of Example 429 (1.0 g, 3.6 mmol) in dry tetrahydrofuran (25 mL) was stirred at 0° C. A solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (1 M, 4 mL, 4 mmol) was added and stirring was continued for 40 min. Benzyl chloride (0.51 g, 0.46 mL, 4 mmol) was added; the reaction mixture was heated to reflux temperature and stirred for 23 h. The reaction mixture was cooled to ambient temperature, poured onto water, basified with a 1 N NAOH solution and extracted with ethyl acetate three times. The-combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo. Column chromatography (CHCl3: MeOH::9:1) gave the title compound (455 mg), a yellow oil: 1 H-NMR (CDCl3, 200 MHz): 7.7 (dd, 2H, J=8,6), 7.2-7.0 (m, 5H), 7.0 (t, 2H, J=8), 3.65-3.55 (m, 1H), 3.2-2.9 (m, 4H), 2.25 (d, 2H, J=7), 2.0-1.7 (m, 4H), 1.65-1.4 (m, 3H), 0.9-0.75 (m, 1H), 0.55-0.45 (m#2H), 0.15-0.05 (m, 2H); HRMS: Calcd for C24 H28 FNO: 365.2155; Found: 365.2156.
A mixture of 1-(cyclopropylmethyl)-4-(4'-cyanophenoxy)methylpiperidine (Example 515, 0.75 g, 2.8 mmol), sodium azide (0.2 g, 3 mmol), ammonium chloride (0.15 g, 3 mmol) and N,N-dimethylformamide (10 mL) was stirred at 100°-120° C. for 23 h. The excess solvent was distilled in vacuo; the residue was suspended in water. A concentrated hydrochloride solution was added until pH=1. The solid formed was filtered, washed with water and dried in vacuo. The title compound (100 mg) had the following analytical data: 1 H-NMR (DMSO-d6, 300 MHz): 7.9 (d, 2H, J=7), 7.0 (d, 2H? J=7)p 3.95 (d, 2H, J=6), 3.45 (br d,, 2H,, J=9), 2.9-2.75 (m, 3H), 2.1-1.9 (m, 3H), 1.7-1.5, (m, 2H), 1.1-1.0 (m, 1H), 0.7-0.6 (m, 2H), 0.45-0.3 (m, 2H); MS:313.
A solution of 4-bromoanisole (1.87 g, 10 mmol) in dry tetrahydrofuran (20 mL) was cooled to -78° C. with stirring under a nitrogen atmosphere. A solution of t-butyl lithium in pentane (1.7 M, 11.8 mL, 20 mmol) was added dropwise. The reaction mixture was stirred at -78° C. for 1 h. A solution of freshly-fused zinc chloride (2.04 g, 15 mmol) in dry tetrahydrofuran (20 mL) was added; the reaction mixture was warmed to -20° C. over 20 min, then cooled to -78° C. A solution of 1-bromo-4-t-butyl-dimethylsilyloxybenzene (2.86 g, 10 mmol) in dry tetrahydrofuran (10 mL) was added, followed by tetrakis (triphenylphosphine)palladium (0) (1.15 g, 1 mmol). The reaction was warmed to 50° C. and stirred for 21 h. The reaction mixture was poured onto a saturated NH4 Cl solution and extracted three times with ethyl acetate. Drying over magnesium sulfate, filtration and removed in vacuo afforded the crude product.
Column chromatography, first with ethyl acetatehexanes (1:9), then hexanes, afforded the title compound, a solid (2.2 g): 1 H-NMR (CDCl3, 300 MHz): 7.45 (d, 2H, J=8), 7.4 (d, 2H, J=8), 6.95 (d, 2H, J=8), 6.9 (d, 2H, J=8), 3.85 (s, 3H), 1.0 (s, 9H), 0.25 (s, 6H). The product was still contaminated with trace amounts of triphenylphosphine and starting silyl ether.
Using the procedure described for Example 551, 4-bromothioanisole (2.03 g, 10 mmol) was converted to the title compound, a solid (0.51 g): 1 H-NMR (CDCl3, 300 MHz): 7.5 (d, 2H, J=8), 7.45 (d, 2H, J=8), 6.9 (d, 2H, J=8), 6.7 (d, 2H, J=8), 2.5 (s, 3H), 1.0 (s, 9H), 0.2 (s, 6H). This product was also contaminated with triphenylphosphine and starting bromide.
Using the procedure described for Example 551, 4-bromofluorobenzene (1.75 g, 10 mmol) was reacted to give the title compound (2.94 g): 1 H-NMR (CDCl3, 300 MHz): 7.5 (dd, 2H, J=8,6), 7.4 (d, 2H, J=8), 7.1 (br t, 2H, J=8), 6.9 (d, 2H, J=8), 6.7 (d, 2H, J=8), 1.0 (s, 9H), 0.25 (s, 6H). This product was contaminated with triphenylphosphine and starting silyl ether.
Using the procedure of Example 551, 4-bromofluorobenzene (1.75 g, 10 mmol) was metallated and coupled with ethyl 4-bromobenzoate (2.28 g, 10 mmol) to give the title compound after chromatography (ethyl acetate-hexanes (1:9) (0.7 g)): 1 H-NMR (CDCl3, 300 MHz): 8.1 (d, 2H, J=8), 7.65-7.5 (m, 4H), 7.15 (t, 2H, J=8), 4.4 (q, 2H, J=7), 1.4 (t, 3H, J=7); MS:244.
Examples 555 through 557 were prepared according to the-methods described for Example 1A (Table 19).
TABLE 19
______________________________________
##STR37##
Ex. R m bp (°C.)
______________________________________
555 2-CH.sub.3 0 145-150 (0.5 mm Hg) (a)
556 2,2-Cl.sub.2 -1-CH.sub.3
0 (b)
557 H 1 145-150 (0.2 mm Hg) (c)
______________________________________
Footnotes for Table 19
(a) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 4.7-4.5(m, 1H), 4.3-4.1(m, 1H),
3.6-3.4(m, 2H), 3.1(br t, 1H, J=7), 2.6(br t, 1H, J=7), 2.0-1.6(m, 5H),
1.5-1.0(m, 4H), 1.1(d, 3H, J=7), 0.65-0.55(m, 1H): MS: 197.
(b) mp = 105-107°C.; .sup.1 HNMR (CDCl.sub.3, 300 MHz): 4.6(br t,
1H, J=7), 3.95(br t, 1H, J=7), 3.6-3.5(m, 2H), 3.25(m, 1H), 2.8-2.6(m,
1H), 2.1-1.7(m, 6H), 1.55(d, 3H, J=7), 1.5-1.1(m, 2H); MS: 265.
(c) .sup.1 HNMR (CDCl.sub.3, 300 MHz): 4.65(br d, 1H, J=10), 3.9(br d, 1H
J=10), 3.55-3.45(m, 2H), 3.1-2.9(m, 2H), 2.65-2.5(m, 1H), 2.3(d, 2H, J=7)
2.0-1.6(m, 4H), 1.3-1.0(m, 4H).
The compounds of this invention and their pharmaceutically acceptable salts possess psychotropic properties, particularly antipsychotic activity of good duration with selective sigma receptor antagonist activities while lacking the typical movement disorder side-effects of standard dopamine receptor antagonist antipsychotic agents. These compounds may also be useful as antidotes for certain psychotomimetic agents such as phencyclidine (PCP), and as antidyskinetic agents.
Male Hartley guinea pigs (250-300 g, Charles River) were sacrificed by decapitation. Brain membranes were prepared by the method of Tam (Proc. Natl. Acad. Sci. USA 80: 6703-6707, 1983). Whole brains were homogenized (20 seconds) in 10 vol (wt/vol) of ice-cold 0.34 M sucrose with a Brinkmann Polytron (setting 8). The homogenate was centrifuged at 920×g for 10 minutes. The supernatant was centrifuged at 47,000×g for 20 minutes. The resulting membrane pellet was resuspended in 10 vol (original wt/vol) of 50 mM Tris HCl (pH 7.4) and incubated at 37° C. for 45 minutes to degrade and dissociate bound endogenous ligands. The membranes were then centrifuged at 47,000×g for 20 minutes and resuspended in 50 mM Tris HCl (50 mL per brain).
0.5 mL aliquots of the membrane preparation were incubated with unlabeled drugs, 1 nM (+)-[3 H]SKF 10,047 in 50 mM Tris HC1, pH 7.4, in a final volume of 1 mL. Nonspecific binding was measured in the presence of 10 μM (+)-SKF 10,047. The apparent dissociation constant (Kd) for (+)-[3 H]SKF 10,047 is 50 nM. After 45 minutes of incubation at room temperature, samples were filtered rapidly through Whatman GF/C glass filters under negative pressure, and washed 3 times with ice-cold Tris buffer (5 mL).
IC50 s were calculated from log-logit plots. Apparent Ki s were calculated from the equation, Ki =IC50 /1+(L/Kd)] (4), where L is the concentration of radioligand and Kd is its dissociation constant. Data are shown in Table I.
Membranes were prepared from guinea pig striatum by the method described for sigma receptor binding. The membranes were then resuspended in 50 mM Tris HCl (9 mL per brain).
0.5 mL aliquots of the membrane preparation were incubated with unlabeled drugs, and 0.15 nM [3 H]spiperone in a final volume of 1 mL containing 50 mm Tris HCl, 120 mM NaCl and 1 mM MgCl2 (pH 7.7). Nonspecific binding was measured in the presence of 100 nM (+)-butaclamol. After 15 minutes of incubation at 37° C., samples were filtered rapidly through Whatman GF/C glass filters under negative pressure, and washed three times with ice-cold binding buffer (5 mL).
IC50 S were calculated from log-logit plots. Apparent Ki s were calculated from the equation Ki =IC50 [1+(L/Kd)](4), where L is the concentration of radioligand and Kd is its dissociation constant. Data are shown in Table I.
The data in Table I indicate that haloperidol, a typical antipsychotic drug, has potent binding affinity for both the sigma and dopamine receptors. This binding profile of haloperidol reflects the therapeutic activity as well as the motor side effects caused by antagonism of the dopamine receptors. In contrast, the examples of this invention shown in Table I indicate potent and selective binding affinity for sigma receptors without binding to the dopamine receptors. Therefore these compounds are not expected to produce the extrapyramidal symptoms that are typical of that produced by haloperidol and other typical antipsychotics that are dopamine receptor antagonists.
This is a modification of the method of Yen et al. (Arch. Int. Pharmacodyn. 123: 179-185, 1959) and Jannsen et al. (J. Pharmacol. Exp. Ther. 129: 471-475, 1960). Male Balb/c mice (Charles River) were used. After 2 weeks of isolation in plastic cages (11.5×5.75×6 in) the mice were selected for aggression by placing a normal group-housed mouse in the cage with the isolate for a maximum of 3 minutes. Isolated mice failing to consistently attack an intruder were eliminated from the colony.
Drug testing was carried out by treating the isolated mice with test drugs or standards. Fifteen minutes after dosing with test drugs by the oral route, one isolated mouse was removed from its home cage and placed in the home cage of another isolate. Scoring was a yes or no response for each pair. A maximum of 3 minutes was allowed for an attack and the pair was separated immediately upon an attack. Selection of home cage and intruder mice was randomized for each test. Mice were treated and tested twice a week with at least a 2 day washout period between treatments.
As shown in Table II, haloperidol and Examples 1, 228, 409, 493 and 494 all have potent activities in inhibiting the isolation-induced aggressive behavior indicating psychotropic activities.
Male Sprague-Dawley rats (CD/CR, Charles River), weighing 190-290 g, were used for surgery. In order to spare nonadrenergic neurons, rats were injected with 25 mg/kg imipramine i.p. 30 minutes before surgery. The rats were anesthetized with a 1:1.2 ratio mixture of Xylazine:Ketamine given 0.1 mL/100 g body weight i.m. A Ringers-Wydaze (100:0.01) solution was given to prevent dehydration. Dopamine was depleted in the right striatum by injecting the neurotoxin 6-hydroxydopamine (6-OHDA) into the substantia nigra of the right cerebral hemisphere. Five mg of 6-OHDA was dissolved in 5 mL of a 0.04% ascorbic acid solution which had been deoxygenated with nitrogen. Five μL of the 6-OHDA solution was injected into the substantia nigra through a 26 gauge needle over a five minute period. Stereotaxic injection coordinates were -2.5 mm posterior to bregma, -2.1 mm right of the midsagittal suture, and -8.6 mm below the skull surface with the incisor bar set at +5.0 mm. Following surgery they were given 10 days to recover while housed four per cage (45.0 L×20.0 H×26.0 W) with ALPHA-dri bedding and ad lib access to Pro-Lab rodent chow and deionized water. Following recovery, the wood clips were removed, the rats were individually housed in suspended cages, and they were placed on a restricted diet so that their weight did not exceed 375 g. At all times they were housed in the animal care facility under a 12-12 hour light/dark cycle (light on at 6:00 h, light off at 18:00 h).
Rotation rate and direction were determined with Coulbourn Instruments Rotometry Monitors. Clockwise and counter clockwise rotations were recorded at 30 and 60 minute intervals. The rats were examined for correct lesion location by testing for rotational activity induced by s.c. injections of 3.0 mg/kg D-amphetamine SO4, and 2.0 mg/kg PCP HCl, respectively. These drugs were administered in the following sequence: Amphetamine was given 30 second before testing. Seven days later, the rats were injected with PCP 30 seconds before testing. Only those rats with an ipsilateral rotation rate of 2.5 turns per minute or higher were used in subsequent tests.
Methocel® or test drugs were administered by the oral route (p.o.) 20 minutes before testing. Phencyclidine (1.5 mg/kg) was given s.c. immediately before testing.
The data were analyzed with an analysis of variance statistical test and individual comparisons of each dose of test drug to control were made with Dunnett's multiple range test. The ED50 was calculated with a Litchfield and Wilcoxon test using percent of control values. Data are shown in Table III.
This is a modification of the method of Costall and Naylor (Psychopharmacologia (Berl.), 43, 69-74, 1975). Male CD rats (Charles River) weighing 250-300 g were treated with test drugs and standards by the oral route and tested for the presence of catalepsy 30 minute, 60 minute, and 90 minute after treatment. To test for catalepsy, each rat is placed with its front paws over a 10 cm high horizontal bar. The intensity of catalepsy is measured by the length of time it takes the animal to move both forelegs to the table. A time of 20 seconds is considered maximal catalepsy. Data is shown in Table III.
As shown in Table III, both haloperidol and Example 494 have potent activity in inhibiting the potent hallucinogen PCP-induced turning behavior in rats, supporting their use for treatment of psychosis. In the catalepsy test which is a model for extrapyramidal symptoms, haloperidol is very potent in producing catalepsy and this agrees well with the side-effect profile of haloperidol in the clinic. In contrast, Example 494 does not produce catalepsy and suggests very low potential for extrapyramidal symptoms and tardive dyskinesia.
TABLE I ______________________________________ Receptor Binding Affinity Example Sigma (D-2) ______________________________________ Haloperidol +++ +++ 1 +++ - 230 +++ - 233 ++ - 234 +++ - 240 ++ - 411 +++ - 412 +++ - 413 ++ - 416 +++ - 435 +++ - 442 ++ - 504 +++ - 505 ++ - 506 ++ - 544 ++ - 539 + - 541 ++ - 542 +++ - 543 + - 547 +++ - 548 +++ + 545 + - 546 +++ - 549 + - 420 +++ - 421 +++ - 422 ++ - 423 +++ - 323 + - 326 ++ - 424 +++ + 425 +++ - 525 +++ + 515 +++ 516 +++ - 511 + - 509 +++ - 533 + - 532 ++ - 530 +++ - ______________________________________
TABLE II
______________________________________
In Vivo
Inhibition of
Isolation-induced
Aggression
______________________________________
Haloperidol +++
1 ++
230 +++
411 +
503 +++
504 +++
______________________________________
TABLE III
______________________________________
In Vivo
Inhibition of
PCP-induced
Example Turning Catalepsy
______________________________________
Haloperidol +++ +++
504 +++ -
______________________________________
Daily dosage ranges from 1 mg to 2000 mg. Dosage forms (compositions) suitable for administration ordinarily will contain 0.5-95% by weight of the active ingredient based on the total weight of the composition.
The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions; it can also be administered parenterally in sterile liquid dosage forms.
Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric-coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
Claims (30)
1. A compound having the formula: ##STR38## or a pharmaceutically acceptable salt thereof, wherein: m is 0 to 3;
n is 0 to 3;
provided m and n are not both O;
p is 0 to 3;
X O or S;
R1, R3, and R7 independently are H, alkyl of 1 to 5 carbon atoms, halogen, NR10 R11, OH, CO2 H, carboalkoxy of 2 to 6 carbon atoms, CN, Ar1, alkoxy of 1 to 5 carbon atoms or alkylthio of 1 to 5 carbon atoms;
R2, R4 and R8 independently are H, alkyl of 1 to 5 carbon atoms, carboalkoxy of 2 to 6 carbon atoms, CN, alkoxy of 1 to 5 carbon atoms or Ar1 ;
provided that R1, R2, R3 and R4 are not alkoxy of 1 to 5 carbon atoms, alkylthio of 1 to 5 carbon atoms, NR10 R11 or OH when X is O or S;
R5 is H, alkyl, halogen, OH or alkenyl;
R6 is H, alkyl of 1 to 5 carbon atoms or Ar1 ;
Ar and Ar1 independently are naphthyl, pyridyl, pyrimidyl, indolyl, quinolinyl, isoquinolinyl, or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, SH, S(O)t alkyl of 1 to 3 carbon atoms, where t is 1, 2 or 3, dialkylamino of 2 to 6 carbon atoms, halogen, OH, alkylamino of 1 to 3 carbon atoms, NH2, CN, NO2, SO3 H, tetrazole, CO2 H, carboalkoxy of 2 to 6 carbon atoms, CONH2, SO2 NH2, COR9, CONR12 R13, SO2 NR12 R13, Ar2, OAr2 or SAr2 ;
Ar2 is naphthyl or phenyl optionally substituted with alkyl of 1 to 3 carbon atoms, haloalkyl of 1 to 3 carbon atoms and 1 to 7 halogen atoms, alkoxy of 1 to 3 carbon atoms, halogen or alkylthio of 1 to 3 carbon atoms;
R9, R10, R11, R12 and R13 independently are H, alkyl of 1 to 5 carbon atoms or phenyl or R10 and R11 taken together are an alkylene chain of 3 to 6 carbon atoms or R12 and R13 taken together are an alkylene chain of 3 to 6 carbon atoms; and
a or b is a double bond or a single bond, provided that both are not double bonds.
2. A compound of claim 1 wherein X is O.
3. A compound of claim 1 wherein m is 0.
4. A compound of claim 1 wherein n and p are each 1.
5. A compound of claim 1 wherein R3 -R5 are H.
6. A compound of claim 1 wherein Ar is phenyl optionally substituted with halogen, OCH3, NH2, NO2 or another phenyl group.
7. A compound of claim 1 wherein:
X is O;
m is 0;
n and p are each 1;
R3 -R5 are H; and
Ar is phenyl optionally substituted with halogen, OCH3, NH2, NO2 or another phenyl group.
8. A compound of claim 7 wherein Ar is 4-fluorophenyl.
9. A compound of claim 7 wherein X is O.
10. A compound of claim 7 wherein:
X is O;
m is 0;
n and p are each 1;
R3, R4 and R5 are H; and
Ar is 4-fluorophenyl.
11. The compound of claim 1 which is 1-(cyclopropylmethyl)-4-(4'-fluorophenoxymethyl) piperidine.
12. The compound of claim 1 which is 1-(cyclopropylmethyl)-4-(4'-fluorophenoxymethyl) piperidine, hydrochloride salt.
13. The compound of claim 1 which is 1-(cyclopropylmethyl)-4-(4'-chlorophenoxymethyl)piperidine.
14. The compound of claim 1 which is 1-(cyclopropylmethyl)-4-(4'-chlorophenoxymethyl)piperidine, hydrochloride salt.
15. The compound of claim 1 which is 1-(cyclopropylmethyl)-4-(4'-nitrophenoxymethyl) piperidine.
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 1.
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 2.
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 3.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 4.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 5.
21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 6.
22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 7.
23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipyschotic effective amount of a compound of claim 8.
24. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 9.
25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of a compound of claim 10.
26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an antipsychotic effective amount of the compound of claim 11.
27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of the compound of claim 12.
28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of the compound of claim 13.
29. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of the compound of claim 14.
30. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antipsychotic effective amount of the compound of claim 15.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/900,774 US5266572A (en) | 1989-09-08 | 1992-06-18 | Antipsychotic 1-cycloalkylpiperidines |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40481389A | 1989-09-08 | 1989-09-08 | |
| US07/570,199 US5109002A (en) | 1989-09-08 | 1990-08-20 | Antipsychotic 1-cycloalkylpiperidines |
| US07/831,886 US5243048A (en) | 1989-09-08 | 1992-02-06 | Antipsychotic 1-cycloalkylpiperidines |
| US07/900,774 US5266572A (en) | 1989-09-08 | 1992-06-18 | Antipsychotic 1-cycloalkylpiperidines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/831,886 Division US5243048A (en) | 1989-09-08 | 1992-02-06 | Antipsychotic 1-cycloalkylpiperidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5266572A true US5266572A (en) | 1993-11-30 |
Family
ID=27503508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/900,774 Expired - Fee Related US5266572A (en) | 1989-09-08 | 1992-06-18 | Antipsychotic 1-cycloalkylpiperidines |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US5266572A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294841A (en) * | 1978-12-05 | 1981-10-13 | Pharmindustrie | Derivatives of 1-phenyl 3-(4-piperidyl) 1-propanone usable as drugs |
-
1992
- 1992-06-18 US US07/900,774 patent/US5266572A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294841A (en) * | 1978-12-05 | 1981-10-13 | Pharmindustrie | Derivatives of 1-phenyl 3-(4-piperidyl) 1-propanone usable as drugs |
Non-Patent Citations (5)
| Title |
|---|
| Eistetter et al, CA95: 24830h, 1981. * |
| Irwin et al, J. Med. Chemistry, vol. 15 (6), pp. 690 692, 1972. * |
| Irwin et al, J. Med. Chemistry, vol. 15 (6), pp. 690-692, 1972. |
| Tr zellaar et al, CA96: 123074s, 1982. * |
| Tryzellaar et al, CA96: 123074s, 1982. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5296479A (en) | Treatment of psychosis using 1-cycloalkylpiperidines | |
| US5116846A (en) | N-aralkyl piperidine derivatives as psychotropic drugs | |
| US5532243A (en) | Antipsychotic nitrogen-containing bicyclic compounds | |
| JPH07252216A (en) | Cyclic amine derivative | |
| NO174505B (en) | Analogous Procedures for Preparation of Therapeutically Active 1,4-Disubstituted Piperidinyl Compounds | |
| EP0861832A1 (en) | Novel tetrahydropyridine derivatives | |
| IE904462A1 (en) | Muscarinic receptor antagonists | |
| HU195804B (en) | Process for preparing piperidine derivatives and medical compositions containing them | |
| WO1991010650A1 (en) | Piperidine and pyrrolidine derivatives | |
| EP0508988B1 (en) | Muscarinic receptor antagonists | |
| HU193233B (en) | Process for preparing new pyrrolo-benzoxazepines | |
| CA2072520A1 (en) | 2-(1-piperidyl) ethanol derivatives, their preparation and their therapeutic application | |
| US5486527A (en) | Anticholinergic agents | |
| US5266572A (en) | Antipsychotic 1-cycloalkylpiperidines | |
| US5243048A (en) | Antipsychotic 1-cycloalkylpiperidines | |
| EP0511222B1 (en) | Disubstituted piperidines and pyrrolidines as anticholinergic agents | |
| US5607950A (en) | Muscarinic receptor antagonists | |
| EP2099780B1 (en) | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | |
| EP0364091B1 (en) | Antipsychotic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)butyl bridged bicyclic imides | |
| KR790001028B1 (en) | Aprocess for prearing novel 1,3,4-trisubstituted-4-arylpiperidines | |
| JPS6135177B2 (en) | ||
| WO1991009014A1 (en) | Muscarinic receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| AS | Assignment |
Owner name: DUPONT PHARMACEUTICALS COMPANY, DELAWARE Free format text: CHANGE OF NAME;ASSIGNOR:DUPONT MERCK PHARMACEUTICAL COMPANY, THE;REEL/FRAME:009586/0702 Effective date: 19980701 |
|
| REMI | Maintenance fee reminder mailed | ||
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20051130 |